

Pre-exposure prophylaxis to prevent the acquisition of
effectiveness results from the pilot phase of a pragmatic

Lancet, The

387, 53-60

DOI: [10.1016/s0140-6736\(15\)00056-2](https://doi.org/10.1016/s0140-6736(15)00056-2)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Preexposure Prophylaxis for HIV Prevention. <i>Annals of Internal Medicine</i> , 2015, 163, 941-948.	2.0	1
3	Pre-exposure prophylaxis for South African adolescents: What evidence?. <i>South African Medical Journal</i> , 2015, 105, 907.	0.2	21
4	2015 – a seminal year for HIV biomedical prevention. <i>Journal of the International AIDS Society</i> , 2015, 18, 20814.	1.2	3
5	The Art of HIV Elimination: Past and Present Science. <i>Journal of AIDS & Clinical Research</i> , 2015, 6, .	0.5	10
6	Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows. <i>BMJ</i> , The, 2015, 351, h4860.	3.0	0
7	Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv126.	0.4	9
8	PrEP: Preparation to be PROUD of. <i>Nature Reviews Urology</i> , 2015, 12, 596-596.	1.9	1
9	Are randomised controlled trials always required?. <i>Lancet HIV</i> , the, 2015, 2, e460-e461.	2.1	2
10	Global implementation of PrEP as part of combination HIV prevention - Unsolved challenges. <i>Journal of the International AIDS Society</i> , 2016, 19, 21479.	1.2	0
11	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-155.	0.3	63
12	HIV-1 prophylactic vaccines: state of the art. <i>Journal of Virus Eradication</i> , 2016, 2, 5-11.	0.3	12
13	PrEP in Europe - expectations, opportunities and barriers. <i>Journal of the International AIDS Society</i> , 2016, 19, 21103.	1.2	24
14	Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. <i>HIV/AIDS - Research and Palliative Care</i> , 2016, Volume 8, 157-164.	0.4	29
15	No one left behind: how are we doing in the roll-out of PrEP as part of combination HIV prevention?. <i>Journal of the International AIDS Society</i> , 2016, 19, 21364.	1.2	11
16	Stop stalling and make PrEP for HIV available now. <i>BMJ</i> , The, 2016, 353, i3160.	3.0	0
17	Sexual transmission of HIV and the law: an Australian medical consensus statement. <i>Medical Journal of Australia</i> , 2016, 205, 409-412.	0.8	6
18	New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections. <i>Journal of Sexually Transmitted Diseases</i> , 2016, 2016, 1-10.	1.0	1
19	Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20791.	1.2	24

#	ARTICLE	IF	CITATIONS
20	Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. <i>Journal of the International AIDS Society</i> , 2016, 19, 21113.	1.2	32
21	Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1 "Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. <i>PLoS Medicine</i> , 2016, 13, e1002099.	3.9	166
22	Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. <i>Journal of the International AIDS Society</i> , 2016, 19, 21165.	1.2	20
23	PrEP, Truvada, and Gilead. <i>BMJ</i> , The, 2016, 354, i4800.	3.0	1
24	Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings. <i>Evidence-Based Medicine</i> , 2016, 21, 99-99.	0.6	0
25	Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. <i>PLoS Medicine</i> , 2016, 13, e1002132.	3.9	70
26	Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures. <i>PLoS ONE</i> , 2016, 11, e0157061.	1.1	28
27	Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. <i>PLoS ONE</i> , 2016, 11, e0157742.	1.1	60
28	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	3.8	533
29	Human Immunodeficiency Virus Prevention With Preexposure Prophylaxis in Sexually Transmitted Disease Clinics. <i>Sexually Transmitted Diseases</i> , 2016, 43, 277-282.	0.8	11
30	Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities. <i>Aids</i> , 2016, 30, 2131-2133.	1.0	2
31	Statistical issues in trials of preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 116-121.	1.5	5
32	The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 80-86.	1.5	84
33	Interventions to strengthen the HIV prevention cascade: a systematic review of reviews. <i>Lancet HIV</i> , the, 2016, 3, e307-e317.	2.1	120
34	The global response to HIV in men who have sex with men. <i>Lancet</i> , The, 2016, 388, 198-206.	6.3	188
35	Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3759-3766.	1.4	22
36	Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men. <i>Aids</i> , 2016, 30, 2251-2252.	1.0	157
37	High Willingness to Use HIV Pre-Exposure Prophylaxis Among Transgender Women in Argentina. <i>Transgender Health</i> , 2016, 1, 266-273.	1.2	22

#	ARTICLE	IF	CITATIONS
38	Preventing HIV among Women – A Step Forward, but Much Farther to Go. <i>New England Journal of Medicine</i> , 2016, 375, 2195-2196.	13.9	4
39	Treatment and Prevention for female sex workers in South Africa: protocol for the TAPS Demonstration Project. <i>BMJ Open</i> , 2016, 6, e011595.	0.8	15
40	Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. <i>BMJ Open</i> , 2016, 6, e012179.	0.8	19
41	MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw832.	2.9	42
42	Pre-exposure Prophylaxis (PrEP) Use, Seroadaptation, and Sexual Behavior Among Men Who Have Sex with Men, San Francisco, 2004–2014. <i>AIDS and Behavior</i> , 2016, 20, 2791-2797.	1.4	66
43	Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. <i>Medical Clinics of North America</i> , 2016, 100, 927-950.	1.1	11
44	An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. <i>Trials</i> , 2016, 17, 163.	0.7	36
45	Awareness of Pre-exposure Prophylaxis for HIV, Willingness to Use It and Potential Barriers or Facilitators to Uptake Among Men Who Have Sex with Men in Spain. <i>AIDS and Behavior</i> , 2016, 20, 1423-1433.	1.4	29
46	Engagement of Gay Men and Other Men Who Have Sex with Men (MSM) in the Response to HIV: A Critical Step in Achieving an AIDS-Free Generation. <i>AIDS and Behavior</i> , 2016, 20, 330-340.	1.4	22
47	HIV moments and pre-exposure prophylaxis – Authors' reply. <i>Lancet, The</i> , 2016, 387, 1508.	6.3	2
48	HIV moments and pre-exposure prophylaxis. <i>Lancet, The</i> , 2016, 387, 1507-1508.	6.3	11
49	Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4140-4150.	1.4	23
50	Antiretroviral chemoprophylaxis: PROUD and pragmatism. <i>Lancet, The</i> , 2016, 387, 6-7.	6.3	18
51	The challenges of preexposure prophylaxis for bacterial sexually transmitted infections. <i>Clinical Microbiology and Infection</i> , 2016, 22, 753-756.	2.8	10
52	Preexposure Prophylaxis and Patient Centeredness. <i>American Journal of Men's Health</i> , 2016, 10, 353-358.	0.7	2
53	Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States. <i>Journal of Infectious Diseases</i> , 2016, 214, 1800-1807.	1.9	174
54	Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3202-3211.	1.4	9
55	Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. <i>Infectious Diseases and Therapy</i> , 2016, 5, 407-416.	1.8	15

#	ARTICLE	IF	CITATIONS
56	Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1787-1789.	1.9	5
57	Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1423-1429.	4.6	89
58	The HIV prevention cascade: more smoke than thunder?. <i>Lancet HIV</i> ,the, 2016, 3, e286-e288.	2.1	18
59	Multiscale Systemsâ€Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIVâ€1. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 377-387.	1.3	27
60	<i>Editorial Commentary</i> : Can We Afford to Control the HIV Epidemic With Antiretrovirals? Can We Afford Not to Do So?. <i>Clinical Infectious Diseases</i> , 2016, 63, 1505-1507.	2.9	1
62	The benefits and risks of PrEP and kidney function. <i>Lancet HIV</i> ,the, 2016, 3, e501-e502.	2.1	1
63	Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 981-991.	0.5	66
64	TDF-FTC before and after sex reduced HIV infection but increased GI, renal events in men who have sex with men. <i>Annals of Internal Medicine</i> , 2016, 164, JC28.	2.0	0
65	Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?. <i>Clinical Microbiology and Infection</i> , 2016, 22, 757-767.	2.8	10
66	Global challenges in human immunodeficiency virus and syphilis coinfection among men who have sex with men. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1037-1046.	2.0	19
67	Combination HIV prevention options for young women in Africa. <i>African Journal of AIDS Research</i> , 2016, 15, 109-121.	0.3	39
68	Antiretrovirals for HIV Treatment and Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 151.	3.8	7
69	NHS England's HIV scandal. <i>British Journal of Nursing</i> , 2016, 25, 947-947.	0.3	0
70	An overview of the Human Immunodeficiency Virus (HIV). <i>Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals</i> , 2016, 8, 507-514.	0.0	1
71	National leadership needed on HIV Preâ€Exposure Prophylaxis (PrEP) access in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2016, 40, 504-505.	0.8	2
72	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	1.9	40
73	Potential impact of preâ€Exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20942.	1.2	18
74	PrEP implementation in the Asiaâ€Pacific region: opportunities, implementation and barriers. <i>Journal of the International AIDS Society</i> , 2016, 19, 21119.	1.2	60

#	ARTICLE	IF	CITATIONS
75	Controversy surrounds NHS delays over commissioning PrEP. <i>The Prescriber</i> , 2016, 27, 12-13.	0.1	2
76	Reducing HIV incidence using anti-retrovirals: Imperative and achievable. <i>Reviews in Medical Virology</i> , 2016, 26, 387-388.	3.9	0
77	Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. <i>Infectious Diseases of Poverty</i> , 2016, 5, 85.	1.5	46
78	Modeling HIV vaccine trials of the future. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 620-627.	1.5	5
79	Equality in sexual health promotion: a systematic review of effective interventions for black and minority ethnic men who have sex with men. <i>BMC Public Health</i> , 2016, 16, 810.	1.2	26
80	Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies. <i>Trials</i> , 2016, 17, 376.	0.7	51
81	Are you PEPped and PrEPped for travel? Risk mitigation of HIV infection for travelers. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2016, 2, 25.	0.9	6
82	Perceptions of pre-exposure prophylaxis (PrEP) among HIV-negative and HIV-positive men who have sex with men (MSM). <i>Cogent Medicine</i> , 2016, 3, 1256850.	0.7	45
83	Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex. <i>Aids</i> , 2016, 30, 2753-2756.	1.0	37
84	Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers. <i>Medicine (United States)</i> , 2016, 95, e4511.	0.4	36
85	Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation. <i>Medicine (United States)</i> , 2016, 95, e4910.	0.4	14
86	Full House: A Retrospective Analysis of High Sexually Transmitted Infection Prevalence among Adult Film Actors at a Singular Residence. <i>Sexually Transmitted Diseases</i> , 2016, 43, 556-559.	0.8	0
87	Implementation of Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Among Men Who Have Sex With Men at a New England Sexually Transmitted Diseases Clinic. <i>Sexually Transmitted Diseases</i> , 2016, 43, 717-723.	0.8	67
88	The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. <i>Aids</i> , 2016, 30, 2267-2273.	1.0	30
89	Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S145-S153.	0.9	29
90	Ethical Issues to Consider in the Design of HIV Prevention Trials Involving Transgender People. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S252-S255.	0.9	5
91	Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S230-S234.	0.9	17
92	Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 540-546.	0.9	238

#	ARTICLE	IF	CITATIONS
93	Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. <i>Journal of the International AIDS Society</i> , 2016, 19, 21108.	1.2	34
94	Shigellosis in men who have sex with men: an overlooked opportunity to counsel with pre-exposure prophylaxis for HIV. <i>International Journal of STD and AIDS</i> , 2016, 27, 1236-1238.	0.5	3
95	Correlates of Awareness of and Willingness to Use Pre-exposure Prophylaxis (PrEP) in Gay, Bisexual, and Other Men Who Have Sex with Men Who Use Geosocial-Networking Smartphone Applications in New York City. <i>AIDS and Behavior</i> , 2016, 20, 1435-1442.	1.4	67
96	Pre-exposure prophylaxis as HIV prevention in the UK. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 150-152.	1.1	3
97	Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1519-1520.	1.9	7
98	AIDS 2016: from aspiration to implementation. <i>Lancet, The</i> , 2016, 387, 2484-2485.	6.3	5
99	Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US. <i>AIDS Research and Therapy</i> , 2016, 13, 5.	0.7	76
100	Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia. <i>Infection, Genetics and Evolution</i> , 2016, 46, 256-268.	1.0	26
101	Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?. <i>Journal of Infectious Diseases</i> , 2016, 214, 983-985.	1.9	1
102	Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. <i>AIDS and Behavior</i> , 2016, 20, 1499-1513.	1.4	41
103	The European preexposure prophylaxis revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 74-79.	1.5	19
104	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	1.1	76
105	Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 48-55.	0.6	66
106	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	13.9	624
107	Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv221.	0.4	11
108	HIV Risk Behaviors, Perceptions, and Testing and Preexposure Prophylaxis (PrEP) Awareness/Use in Grindr-Using Men Who Have Sex With Men in Atlanta, Georgia. <i>Journal of the Association of Nurses in AIDS Care</i> , 2016, 27, 133-142.	0.4	65
109	Towards preparedness for PrEP: PrEP awareness and acceptability among MSM at high risk of HIV transmission who use sociosexual media in four Celtic nations: Scotland, Wales, Northern Ireland and The Republic of Ireland: an online survey. <i>Sexually Transmitted Infections</i> , 2016, 92, 279-285.	0.8	37
110	Sources of HIV infection among men having sex with men and implications for prevention. <i>Science Translational Medicine</i> , 2016, 8, 320ra2.	5.8	106

#	ARTICLE	IF	CITATIONS
111	HIV protection with PrEP – implications for controlling other STIs. <i>Nature Reviews Urology</i> , 2016, 13, 72-74.	1.9	1
112	Polarised press reporting about HIV prevention: Social representations of pre-exposure prophylaxis in the UK press. <i>Health (United Kingdom)</i> , 2017, 21, 478-497.	0.9	35
113	“PrEP is not ready for our community, and our community is not ready for PrEP”: pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response. <i>Addiction</i> , 2017, 112, 572-578.	1.7	34
114	HIV Pre-exposure Prophylaxis Programs Incorporating Social Applications Can Reach At-Risk Men Who Have Sex With Men for Successful Linkage to Care in Missouri, USA. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 428-430.	0.4	13
116	Global travel and HIV/STI epidemics among MSM: what does the future hold?. <i>Sexual Health</i> , 2017, 14, 51.	0.4	23
117	HIV incidence in an open national cohort of men who have sex with men attending sexually transmitted infection clinics in England. <i>HIV Medicine</i> , 2017, 18, 615-622.	1.0	17
118	Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1236-1246.	1.4	190
119	Young Transgender Women's Attitudes Toward HIV Pre-exposure Prophylaxis. <i>Journal of Adolescent Health</i> , 2017, 60, 549-555.	1.2	64
120	Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. <i>Drug Safety</i> , 2017, 40, 273-283.	1.4	51
121	Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. <i>Drug and Alcohol Dependence</i> , 2017, 173, 107-116.	1.6	57
122	Modelling the evolution of HIV –1 virulence in response to imperfect therapy and prophylaxis. <i>Evolutionary Applications</i> , 2017, 10, 297-309.	1.5	13
123	Progress in HIV vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1018-1030.	1.4	80
124	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 377-383.	0.3	11
125	Post-exposure prophylaxis awareness and use among men who have sex with men in London who use geosocial-networking smartphone applications. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 579-586.	0.6	8
126	Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool. <i>Sexually Transmitted Infections</i> , 2017, 93, 363-367.	0.8	20
127	Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities. <i>Sexually Transmitted Infections</i> , 2017, 93, 52-55.	0.8	62
128	Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. <i>International Journal of Drug Policy</i> , 2017, 43, 33-43.	1.6	157
129	What are the characteristics of, and clinical outcomes in men who have sex with men prescribed HIV postexposure prophylaxis following sexual exposure (PEPSE) at sexual health clinics in England?. <i>Sexually Transmitted Infections</i> , 2017, 93, 207-213.	0.8	10

#	ARTICLE	IF	CITATIONS
130	HIV Pre-Exposure Prophylaxis and Postexposure Prophylaxis in Japan: Context of Use and Directions for Future Research and Action. <i>AIDS Patient Care and STDs</i> , 2017, 31, 60-77.	1.1	3
131	Significant publications on infectious diseases pharmacotherapy in 2015. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 238-252.	0.5	12
132	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. <i>Clinical Infectious Diseases</i> , 2017, 65, 324-327.	2.9	18
133	Better PrEP needed?. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 25-25.	0.3	0
134	Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. <i>Annals of Medicine</i> , 2017, 49, 534-544.	1.5	14
135	Pre-exposure prophylaxis is approved in Scotland. <i>Lancet HIV</i> , 2017, 4, e238-e239.	2.1	8
136	Men who have sex with men with newly-diagnosed HIV are often eligible for HIV pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2017, 28, 629-629.	0.5	0
137	Support Your Client at the Space That They're in: HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 196-204.	1.1	58
138	Risk, safety and sex among male PrEP users: time for a new understanding. <i>Culture, Health and Sexuality</i> , 2017, 19, 1301-1313.	1.0	75
139	Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 712-718.	2.9	186
140	HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2171-2183.	1.3	8
141	High HIV incidence in men who have sex with men attending for postexposure prophylaxis: a service evaluation. <i>Sexually Transmitted Infections</i> , 2017, 93, 214-216.	0.8	13
142	Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. <i>HIV Medicine</i> , 2017, 18, 412-418.	1.0	57
143	MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. <i>Aids</i> , 2017, 31, 1603-1610.	1.0	119
144	Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 184-189.	0.9	5
145	Is it time to start new HIV prevention strategies in Spain?. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 271-272.	0.2	1
146	PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists. <i>AIDS and Behavior</i> , 2017, 21, 1256-1267.	1.4	229
148	Patient support: High-risk behaviour. <i>British Dental Journal</i> , 2017, 222, 497-498.	0.3	0

#	ARTICLE	IF	CITATIONS
149	Culturally Competent Sexual Healthcare as a Prerequisite for Obtaining Preexposure Prophylaxis: Findings from a Qualitative Study. <i>LGBT Health</i> , 2017, 4, 310-314.	1.8	57
151	Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. <i>Aids</i> , 2017, 31, 739-740.	1.0	31
152	Is PrEP Needed for MSM in West Africa? HIV Incidence in a Prospective Multicountry Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e80-e82.	0.9	15
153	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S17-S26.	0.9	80
154	Awareness, Willingness, and Use of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Washington, DC and Miami-Dade County, FL: National HIV Behavioral Surveillance, 2011 and 2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S375-S382.	0.9	44
155	Acceptability and use of a dapivirine vaginal ring in a phase III trial. <i>Aids</i> , 2017, 31, 1159-1167.	1.0	97
156	Assessing the need for a pre-exposure prophylaxis programme using the social media app Grindr®. <i>HIV Medicine</i> , 2017, 18, 772-776.	1.0	16
157	To whom is HIV pre-exposure prophylaxis proposed?. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 299-302.	0.2	4
158	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , 2017, 356, 938-945.	6.0	348
159	HIV preexposure prophylaxis for adolescents and young adults. <i>Current Opinion in Pediatrics</i> , 2017, 29, 399-406.	1.0	33
161	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. <i>Lancet HIV</i> , 2017, 4, e331-e340.	2.1	187
162	Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1760-1768.	1.3	8
163	¿Es el momento de poner en marcha nuevas estrategias de prevención de la infección por VIH en España?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 271-272.	0.3	3
164	The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 467-481.	2.0	3
165	Time to Make the Jump: Translating HIV Pre-exposure Prophylaxis Research Into Real-World Public Health Impact. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e144-e146.	0.9	3
166	HIV Prevention and Treatment: The Evolving Role of the Emergency Department. <i>Annals of Emergency Medicine</i> , 2017, 70, 562-572.e3.	0.3	25
167	Sexually transmissible infection control programs for men who have sex with men – what will they look like in 2020?. <i>Sexual Health</i> , 2017, 14, 126.	0.4	4
168	Antiseptic mouthwash against pharyngeal <i>Neisseria gonorrhoeae</i> : a randomised controlled trial and an in vitro study. <i>Sexually Transmitted Infections</i> , 2017, 93, 88-93.	0.8	64

#	ARTICLE	IF	CITATIONS
169	HIV incidence among gay men and other men who have sex with men in 2020: where is the epidemic heading?. <i>Sexual Health</i> , 2017, 14, 5.	0.4	38
170	As through a glass, darkly: the future of sexually transmissible infections among gay, bisexual and other men who have sex with men. <i>Sexual Health</i> , 2017, 14, 18.	0.4	19
171	Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 8-15.	0.3	0
172	Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1288-1298.	1.4	115
173	How many MSM are taking PrEP: a service evaluation. <i>Sexually Transmitted Infections</i> , 2017, 93, 529-529.	0.8	3
174	Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic. <i>Current HIV/AIDS Reports</i> , 2017, 14, 201-210.	1.1	23
175	HIV prevention trial design in an era of effective pre-exposure prophylaxis. <i>HIV Clinical Trials</i> , 2017, 18, 177-188.	2.0	19
176	Rapidly declining HIV infection in MSM in central London. <i>Lancet HIV</i> , 2017, 4, e482-e483.	2.1	86
177	Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. <i>Journal of the International AIDS Society</i> , 2017, 20, 21885.	1.2	38
178	Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2017, 20, 21580.	1.2	119
179	Toward an Iterative Approach to Preventing HIV Risk Among Young MSM. , 2017, , 315-324.		0
180	Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 501-511.	0.9	60
181	A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. <i>BMJ Open</i> , 2017, 7, e016494.	0.8	12
182	Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. <i>BMJ Open</i> , 2017, 7, e015142.	0.8	19
183	The Role of Phylogenetics as a Tool to Predict the Spread of Resistance. <i>Journal of Infectious Diseases</i> , 2017, 216, S820-S823.	1.9	10
184	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	1.0	47
185	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
186	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e104-e106.	0.9	64

#	ARTICLE	IF	CITATIONS
187	Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. <i>Lancet HIV</i> , 2017, 4, e522-e528.	2.1	69
188	Let's talk about sex: A qualitative study exploring the experiences of HIV nurses when discussing sexual risk behaviours with HIV-positive men who have sex with men. <i>International Journal of Nursing Studies</i> , 2017, 76, 55-61.	2.5	8
189	HIV in retreat?. <i>Reviews in Medical Virology</i> , 2017, 27, e1939.	3.9	0
190	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. <i>JAMA Pediatrics</i> , 2017, 171, 1063.	3.3	178
191	Exploring Sex, HIV and "Sensitive" Space(s) Among Sexual and Gender Minority Young Adults in Thailand. , 2017, , 83-106.		6
192	Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. <i>Aids</i> , 2017, 31, 2179-2191.	1.0	51
193	Challenges and emerging opportunities for the HIV prevention, treatment and care cascade in men who have sex with men in Asia Pacific. <i>Sexually Transmitted Infections</i> , 2017, 93, 356-362.	0.8	27
194	High HIV incidence in men who have sex with men following an early syphilis diagnosis: is there room for pre-exposure prophylaxis as a prevention strategy?. <i>Sexually Transmitted Infections</i> , 2017, 93, 320-322.	0.8	18
195	Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. <i>Lancet HIV</i> , 2017, 4, e402-e410.	2.1	379
196	The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. <i>Aids</i> , 2017, 31, 2007-2016.	1.0	75
197	HIV prevention. <i>Aids</i> , 2017, 31, 1343.	1.0	1
198	Condomless Anal Sex Among HIV-Positive Men Who Have Sex with Men: Biomedical Context Matters. <i>AIDS and Behavior</i> , 2017, 21, 2886-2894.	1.4	10
199	PrEP on demand or every day?. <i>Lancet HIV</i> , 2017, 4, e379-e380.	2.1	6
200	Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 250-258.	0.9	111
201	Impacts of Longitudinal Mentorship to Strengthen the HIV Workforce: Qualitative Evidence of Changes in Clinicians' Knowledge, Attitudes, and Practice. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 938-952.	0.4	3
202	Infección por el VIH/sida: ¿El principio del fin de la primera gran pandemia contemporánea?. <i>Revista Clínica Española</i> , 2017, 217, 468-472.	0.2	2
203	HIV/AIDS infection: The beginning of the end for today's greatest pandemic?. <i>Revista Clínica Española</i> , 2017, 217, 468-472.	0.3	0
204	Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. <i>Lancet HIV</i> , 2017, 4, e465-e474.	2.1	50

#	ARTICLE	IF	CITATIONS
205	HIV pre-exposure prophylaxis (PrEP): effective but controversial. Trends in Urology & Men's Health, 2017, 8, 9-12.	0.2	8
206	Evaluation of the Condom Barriers Scale for Young Black Men Who Have Sex With Men: Reliability and Validity of 3 Subscales. Sexually Transmitted Diseases, 2017, 44, 91-95.	0.8	5
207	Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 56-59.	0.9	89
208	Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 531-538.	0.9	68
209	Distribution of Behavioral Patterns Before Infection Among San Francisco Men Who Have Sex With Men Newly Infected With HIV in 2014. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 528-534.	0.9	3
210	Where next with preexposure prophylaxis?. Current Opinion in Infectious Diseases, 2017, 30, 44-49.	1.3	2
211	Individual Versus Community-Level Risk Compensation Following Preexposure Prophylaxis of HIV. American Journal of Public Health, 2017, 107, 1568-1571.	1.5	48
212	HIV Preexposure Prophylaxis and Condomless Sex: Disentangling Personal Values From Public Health Priorities. American Journal of Public Health, 2017, 107, 1572-1576.	1.5	21
213	Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. Cmaj, 2017, 189, E1448-E1458.	0.9	149
214	Acute Alcohol Consumption Directly Increases HIV Transmission Risk: A Randomized Controlled Experiment. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 493-500.	0.9	34
215	Sexually transmitted infections: challenges ahead. Lancet Infectious Diseases, The, 2017, 17, e235-e279.	4.6	510
216	Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sexually Transmitted Infections, 2017, 93, 590-598.	0.8	39
217	HIV pre-exposure prophylaxis: the primary care implications of prescribing restrictions. British Journal of General Practice, 2017, 67, 324-325.	0.7	1
218	Long-acting cabotegravir for prevention: hope versus reality. Lancet HIV,the, 2017, 4, e322-e323.	2.1	4
219	Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections are associated with systemic CD8+ T-cell activation. Aids, 2017, 31, 2069-2076.	1.0	7
220	A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. Infectious Diseases and Therapy, 2017, 6, 363-382.	1.8	37
222	A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol. BMC Infectious Diseases, 2017, 17, 456.	1.3	44
223	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. Aids, 2017, 31, 1935-1943.	1.0	7

#	ARTICLE	IF	CITATIONS
224	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	0.9	235
225	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	0.9	25
226	Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs. <i>Journal of Infectious Diseases</i> , 2017, 216, 382-386.	1.9	25
227	Antiretroviral treatment for HIV infection: Swedish recommendations 2016. <i>Infectious Diseases</i> , 2017, 49, 1-34.	1.4	24
228	Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. <i>Journal of General Internal Medicine</i> , 2017, 32, 192-198.	1.3	88
229	Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1336-1349.	1.4	103
230	A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. <i>Journal of General Internal Medicine</i> , 2017, 32, 62-70.	1.3	131
231	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 734-740.	0.6	6
232	Low Awareness and Use of Preexposure Prophylaxis in a Diverse Online Sample of Men Who Have Sex With Men in New York City. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 27-33.	0.4	20
233	The Impact of HIV Pre-exposure Prophylaxis (PrEP) Use on the Sexual Health of Men Who Have Sex with Men: A Qualitative Study in Seattle, WA. <i>International Journal of Sexual Health</i> , 2017, 29, 55-68.	1.2	63
234	Healthcare Provider Contact and Pre-exposure Prophylaxis in Baltimore Men Who Have Sex With Men. <i>American Journal of Preventive Medicine</i> , 2017, 52, 55-63.	1.6	29
235	Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil. <i>AIDS and Behavior</i> , 2017, 21, 1278-1287.	1.4	76
236	Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 478-485.	1.3	37
237	¿A quiÃ©n proponer la profilaxis preexposiciÃ³n al virus de la inmunodeficiencia humana?. <i>Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ­nica</i> , 2017, 35, 299-302.	0.3	14
238	Methods and Approaches to HIV Prevention. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 19-24.	0.4	1
239	Community-based, nurse-led post-exposure prophylaxis: results and implications. <i>International Journal of STD and AIDS</i> , 2017, 28, 505-511.	0.5	21
240	Commitment issues: PrEP adherence in injecting drug users. <i>Lancet HIV</i> , 2017, 4, e52-e53.	2.1	4
241	Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". <i>AIDS and Behavior</i> , 2017, 21, 1350-1360.	1.4	72

#	ARTICLE	IF	CITATIONS
242	Pre-exposure prophylaxis for people who inject drugs and their sex partners. <i>Addiction</i> , 2017, 112, 579-580.	1.7	2
243	Top Questions in ID: Pre-exposure Prophylaxis for HIV. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx185.	0.4	1
244	Promoting Pre-exposure Prophylaxis to Prevent HIV Infections Among Sexual and Gender Minority Hispanics/Latinxs. <i>AIDS Education and Prevention</i> , 2017, 29, 389-400.	0.6	28
245	Infecciones de transmisi3n sexual. ¿Les hemos perdido el miedo?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2017, 24, 489-491.	0.0	0
246	Recent advances in pre-exposure prophylaxis for HIV. <i>BMJ: British Medical Journal</i> , 2017, 359, j5011.	2.4	101
247	Sociodemographic and Clinical Factors Associated With Increasing Bacterial Sexually Transmitted Infection Diagnoses in Men Who Have Sex With Men Accessing Care at a Boston Community Health Center (2005-2015). <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx214.	0.4	26
248	Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. <i>Journal of the International AIDS Society</i> , 2017, 20, 21842.	1.2	67
249	Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx061.	0.4	10
250	Expanding the domain of drug delivery for HIV prevention: exploration of the transdermal route. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2017, 34, 551-587.	1.2	13
251	Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016. <i>Eurosurveillance</i> , 2017, 22, .	3.9	14
252	Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)?. <i>Eurosurveillance</i> , 2017, 22, .	3.9	87
253	Highlights from the BHIVA Satellite Symposium, IAS Conference, Paris, France, July 2017: "Tougher times: adapting to increasing demand with declining resources". <i>Journal of Virus Eradication</i> , 2017, 3, 250-252.	0.3	1
254	InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. <i>Journal of Virus Eradication</i> , 2017, 3, 218-222.	0.3	14
255	An HIV-negative Same-sex Male Couple Both Infected with Hepatitis C Virus. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1255-1257.	0.6	0
256	Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era. <i>Viruses</i> , 2017, 9, 281.	1.5	21
257	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
258	Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 137-148.	0.7	20
259	Pre-exposure prophylaxis for HIV prevention in women: current perspectives. <i>International Journal of Women's Health</i> , 2017, Volume 9, 391-401.	1.1	41

#	ARTICLE	IF	CITATIONS
260	Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study. PLoS ONE, 2017, 12, e0175596.	1.1	6
261	Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. PLoS ONE, 2017, 12, e0178170.	1.1	25
262	Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE, 2017, 12, e0178737.	1.1	75
263	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. PLoS ONE, 2017, 12, e0181433.	1.1	9
264	Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. PLoS ONE, 2017, 12, e0185946.	1.1	26
265	Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS ONE, 2017, 12, e0184303.	1.1	18
266	Long-Acting HIV Treatment and Prevention: Closer to the Threshold. Global Health, Science and Practice, 2017, 5, 182-187.	0.6	23
267	Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Medicine, 2017, 15, 217.	2.3	27
268	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. BMC Infectious Diseases, 2017, 17, 734.	1.3	4
269	High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. Journal of the International AIDS Society, 2017, 20, 21472.	1.2	98
270	Pre-exposure prophylaxis for HIV prevention in East and Southern Africa. Canadian Journal of Public Health, 2017, 108, e643-e645.	1.1	3
271	Willingness to use pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Malaysia: findings from a qualitative study. Journal of the International AIDS Society, 2017, 20, 21899.	1.2	32
272	Old Pathogen, New Challenges: A Narrative Review of the Multilevel Drivers of Syphilis Increasing in American Men Who Have Sex With Men. Sexually Transmitted Diseases, 2018, 45, S38-S41.	0.8	15
273	Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control. Journal of Infectious Diseases, 2018, 217, 1522-1529.	1.9	32
274	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nature Medicine, 2018, 24, 491-496.	15.2	123
275	Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies. Sexually Transmitted Diseases, 2018, 45, 615-622.	0.8	52
276	Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. Sexually Transmitted Infections, 2018, 94, 457-462.	0.8	60
277	The Changing Paradigm of Sexually Transmitted Disease Prevention. Sexually Transmitted Diseases, 2018, 45, 573-575.	0.8	2

#	ARTICLE	IF	CITATIONS
278	2016 PREP attitudes in Germany: high awareness and acceptance in MSM at risk of HIV. <i>Infection</i> , 2018, 46, 405-408.	2.3	19
279	Amplifying the Population Health Benefits of PrEP for HIV Prevention. <i>Journal of Infectious Diseases</i> , 2018, 217, 1509-1511.	1.9	9
280	Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 67, 676-686.	2.9	326
281	Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. <i>Journal of the International AIDS Society</i> , 2018, 21, e25105.	1.2	72
282	HIV prevention strategies and risk of infection: a model-based analysis. <i>Epidemiology and Infection</i> , 2018, 146, 1015-1025.	1.0	8
283	Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France. <i>Journal of the International AIDS Society</i> , 2018, 21, e25100.	1.2	50
284	HIV prevention strategies. <i>Medicine</i> , 2018, 46, 293-299.	0.2	1
285	Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25103.	1.2	53
286	Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. <i>Lancet HIV</i> , 2018, 5, e136-e145.	2.1	130
287	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	2.9	50
288	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	2.9	48
289	HIV preexposure prophylaxis: An essential, safe and effective prevention tool for sexual health. <i>Médecine Et Maladies Infectieuses</i> , 2018, 48, 318-326.	5.1	5
290	Intimate Partner Violence Correlates With A Higher HIV Incidence Among MSM: A 12-Month Prospective Cohort Study in Shenyang, China. <i>Scientific Reports</i> , 2018, 8, 2879.	1.6	16
291	Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015. <i>Journal of Infectious Diseases</i> , 2018, 217, 617-621.	1.9	12
292	Achieving 90-90-90 Human Immunodeficiency Virus (HIV) Targets Will Not Be Enough to Achieve the HIV Incidence Reduction Target in Australia. <i>Clinical Infectious Diseases</i> , 2018, 66, 1019-1023.	2.9	28
293	Temporal Fluctuations in Behavior, Perceived HIV Risk, and Willingness to Use Pre-Exposure Prophylaxis (PrEP). <i>Archives of Sexual Behavior</i> , 2018, 47, 2109-2121.	1.2	44
294	Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategies. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 95-101.	1.5	11
295	2016 United Kingdom national guideline on the sexual health care of men who have sex with men. <i>International Journal of STD and AIDS</i> , 2018, , 095646241774689.	0.5	40

#	ARTICLE	IF	CITATIONS
296	Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012–2016. <i>AIDS and Behavior</i> , 2018, 22, 3550-3565.	1.4	37
297	The informal use of antiretroviral medications for HIV prevention by men who have sex with men in South Florida: initiation, use practices, medications and motivations. <i>Culture, Health and Sexuality</i> , 2018, 20, 1185-1198.	1.0	7
298	Intimate Partner Violence and Self-Reported Pre-exposure Prophylaxis Interruptions Among HIV-Negative Partners in HIV Serodiscordant Couples in Kenya and Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 154-159.	0.9	47
299	Targeting Human Immunodeficiency Virus Pre-Exposure Prophylaxis to Adolescent Sexual Minority Males in Higher Prevalence Areas of the United States: A Modeling Study. <i>Journal of Adolescent Health</i> , 2018, 62, 311-319.	1.2	27
300	Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. <i>Aids</i> , 2018, 32, 523-530.	1.0	109
301	The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. <i>Journal of Adolescent Health</i> , 2018, 62, 22-28.	1.2	23
302	Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2018, 37, 387-400.	0.6	27
303	Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 784-792.	0.6	8
304	Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the "Getting to Zero" Era. <i>Clinical Infectious Diseases</i> , 2018, 66, 1027-1034.	2.9	41
305	Wild-type HIV infection despite PrEP: a lot to learn from a case report. <i>Lancet HIV</i> , 2018, 5, e10.	2.1	1
306	Pharmaceutical interactions between antiretroviral and antimalarial drugs used in chemoprophylaxis. <i>Acta Tropica</i> , 2018, 179, 25-35.	0.9	1
307	HIV Education and Sexual Risk Behaviors Among Young Men Who Have Sex with Men. <i>LGBT Health</i> , 2018, 5, 131-138.	1.8	33
308	Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial. <i>BMC Public Health</i> , 2018, 18, 210.	1.2	49
309	When participants get involved: reconsidering patient and public involvement in clinical trials at the MRC Clinical Trials Unit at UCL. <i>Trials</i> , 2018, 19, 95.	0.7	8
310	Trends in the awareness, acceptability, and usage of HIV pre-exposure prophylaxis among at-risk men who have sex with men in Toronto. <i>Canadian Journal of Public Health</i> , 2018, 109, 342-352.	1.1	21
311	Missed Opportunities to Prescribe HIV Pre-Exposure Prophylaxis by Primary Care Providers in Saint Louis, Missouri. <i>LGBT Health</i> , 2018, 5, 250-256.	1.8	23
312	Editorial. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 291-293.	1.5	8
313	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.	1.3	38

#	ARTICLE	IF	CITATIONS
314	The cost-effectiveness of multi-purpose <sc>HIV</sc> and pregnancy prevention technologies in South Africa. <i>Journal of the International AIDS Society</i> , 2018, 21, e25064.	1.2	23
315	HIV Preexposure Prophylaxis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1261.	3.8	206
316	What qualities in a potential HIV pre-exposure prophylaxis service are valued by black men who have sex with men in London? A qualitative acceptability study. <i>International Journal of STD and AIDS</i> , 2018, 29, 760-765.	0.5	11
317	Implementing preexposure prophylaxis among key populations. <i>Aids</i> , 2018, 32, 829-830.	1.0	6
318	The new MTV generation: Using methamphetamine, Truvada, and Viagra to enhance sex and stay safe. <i>International Journal of Drug Policy</i> , 2018, 55, 197-204.	1.6	54
319	A Global Estimate of the Acceptability of Pre-exposure Prophylaxis for HIV Among Men Who have Sex with Men: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2018, 22, 1063-1074.	1.4	137
320	InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtricitabine in London - analysis of pharmacokinetics, safety and outcomes. <i>HIV Medicine</i> , 2018, 19, 1-6.	1.0	28
321	An Evaluation of a Clinical Pre-Exposure Prophylaxis Education Intervention among Men Who Have Sex with Men. <i>Health Services Research</i> , 2018, 53, 2249-2267.	1.0	17
322	Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China. <i>AIDS and Behavior</i> , 2018, 22, 1217-1227.	1.4	51
323	Community-based screening of hepatitis C with a one-step <sc>RNA</sc> detection algorithm from dried blood spots: Analysis of key populations in Barcelona, Spain. <i>Journal of Viral Hepatitis</i> , 2018, 25, 236-244.	1.0	29
324	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV</i> , 2018, 5, e68-e78.	2.1	96
325	Working towards HIV prevention choices for women. <i>Lancet HIV</i> , 2018, 5, e60-e61.	2.1	1
326	Pre-exposure prophylaxis is cost-effective for HIV in the UK. <i>Lancet Infectious Diseases</i> , 2018, 18, 10-11.	4.6	2
327	HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 466-472.	0.6	4
328	The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 31-40.	0.9	54
329	Whole genome sequencing of <i>Neisseria gonorrhoeae</i> reveals transmission clusters involving patients of mixed HIV serostatus. <i>Sexually Transmitted Infections</i> , 2018, 94, 138-143.	0.8	19
330	Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. <i>Lancet Infectious Diseases</i> , 2018, 18, 85-94.	4.6	80
331	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. <i>Clinical Microbiology and Infection</i> , 2018, 24, 540-545.	2.8	13

#	ARTICLE	IF	CITATIONS
332	Ethical public health issues for the use of informal PrEP. <i>Global Public Health</i> , 2018, 13, 1382-1387.	1.0	16
333	Perceived need of, and interest in, HIV pre-exposure prophylaxis amongst men who have sex with men attending three sexual health clinics in London, UK. <i>International Journal of STD and AIDS</i> , 2018, 29, 435-442.	0.5	15
334	Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 168-170.	0.5	1
335	Pre-Exposure Prophylaxis (PrEP) Use and Condomless Anal Sex: Evidence of Risk Compensation in a Cohort of Young Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 358-364.	0.9	90
336	Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2018, 47, 2101-2107.	1.2	50
337	Are Anal Sex Roles Associated with Preferences for Pre-Exposure Prophylaxis Administration Modalities Among Men Who Have Sex with Men?. <i>Archives of Sexual Behavior</i> , 2018, 47, 2123-2133.	1.2	8
338	Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. <i>Lancet Infectious Diseases</i> , 2018, 18, 308-317.	4.6	175
339	Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 206-211.	0.9	23
340	Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. <i>AIDS and Behavior</i> , 2018, 22, 1228-1238.	1.4	31
341	Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. <i>AIDS and Behavior</i> , 2018, 22, 1209-1216.	1.4	23
342	Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 163-168.	0.8	36
343	Rectal Douching Among Men Who Have Sex with Men in Paris: Implications for HIV/STI Risk Behaviors and Rectal Microbicide Development. <i>AIDS and Behavior</i> , 2018, 22, 379-387.	1.4	17
344	Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 9-17.	0.6	76
345	Does pre-exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review. <i>Journal of Clinical Nursing</i> , 2018, 27, 3254-3265.	1.4	47
346	Demand for pre-exposure prophylaxis for HIV and the impact on clinical services: Scottish men who have sex with men perspectives. <i>International Journal of STD and AIDS</i> , 2018, 29, 273-277.	0.5	6
347	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194.	1.0	14
348	Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 330-338.	0.9	20
349	Canadian guidelines on HIV pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP): Discussion beyond the guidelines and commentary on the role of infectious diseases specialists. <i>Jammi</i> , 2018, 3, 165-177.	0.3	3

#	ARTICLE	IF	CITATIONS
350	Elimination prospects of the Dutch HIV epidemic among men who have sex with men in the era of preexposure prophylaxis. <i>Aids</i> , 2018, 32, 2615-2623.	1.0	18
351	Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 347-351.	0.9	31
352	Users of a National Directory of PrEP Service Providers: Beliefs, Self-Efficacy, and Progress Toward Prescription. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, e28-e30.	0.9	8
353	PrEP: pre-exposure prophylaxis for HIV prevention. <i>Trends in Urology & Men's Health</i> , 2018, 9, 22-24.	0.2	0
354	Acceptability and tolerability of and adherence to HIV preexposure prophylaxis among Toronto gay and bisexual men: a pilot study. <i>CMAJ Open</i> , 2018, 6, E611-E617.	1.1	4
355	Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 186-194.	0.9	72
356	PrEParing for the unexpected: mechanisms and management of HIV pre-exposure prophylaxis failure. <i>Future Virology</i> , 2018, 13, 747-759.	0.9	3
357	Prevençã³n primaria. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 31-34.	0.3	0
358	Redefining Prevention and Care: A Status-Neutral Approach to HIV. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy097.	0.4	79
360	Increasing prevalence of self-reported HIV preexposure prophylaxis use in published surveys. <i>Aids</i> , 2018, 32, 2633-2635.	1.0	27
361	Outcomes of Preexposure Prophylaxis Referrals From Public STI Clinics and Implications for the Preexposure Prophylaxis Continuum. <i>Sexually Transmitted Diseases</i> , 2018, 45, 50-55.	0.8	32
362	Human Immunodeficiency Virus/Sexually Transmitted Infection Counseling and Testing Services Received by Gay and Bisexual Men Using Preexposure Prophylaxis at Their Last PrEP Care Visit. <i>Sexually Transmitted Diseases</i> , 2018, 45, 798-802.	0.8	13
363	Changing pattern of sexually transmissible infections and HIV diagnosed in public sexual health services compared with other locations in New South Wales, 2010â€“14. <i>Sexual Health</i> , 2018, 15, 366.	0.4	6
364	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	3.9	126
365	A systematic review of adherence to oral pre-exposure prophylaxis for HIV â€“ how can we improve uptake and adherence?. <i>BMC Infectious Diseases</i> , 2018, 18, 581.	1.3	146
366	HIV pre-exposure prophylaxis in South East Asia: A focused review on present situation. <i>International Journal of Infectious Diseases</i> , 2018, 77, 113-117.	1.5	13
367	Brief Report: HIV Pre-exposure Prophylaxis Engagement Among Adolescent Men Who Have Sex With Men: The Role of Parentâ€“Adolescent Communication About Sex. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 453-457.	0.9	30
368	Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. <i>Aids</i> , 2018, 32, 2161-2169.	1.0	45

#	ARTICLE	IF	CITATIONS
369	Potential Impact of HIV Preexposure Prophylaxis Among Black and White Adolescent Sexual Minority Males. <i>American Journal of Public Health</i> , 2018, 108, S284-S291.	1.5	26
370	Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. <i>Lancet HIV</i> , 2018, 5, e629-e637.	2.1	273
371	Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. <i>PLoS ONE</i> , 2018, 13, e0209484.	1.1	23
372	Improving the impact of HIV pre-exposure prophylaxis implementation in small urban centers among men who have sex with men: An agent-based modelling study. <i>PLoS ONE</i> , 2018, 13, e0199915.	1.1	14
373	HIV incidence among sexual health clinic attendees in England: First estimates for black African heterosexuals using a biomarker, 2009-2013. <i>PLoS ONE</i> , 2018, 13, e0197939.	1.1	6
374	Project ECHO: telementoring to educate and support prescribing of HIV pre-exposure prophylaxis by community medical providers. <i>Sexual Health</i> , 2018, 15, 601.	0.4	32
375	No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. <i>PLoS ONE</i> , 2018, 13, e0206577.	1.1	3
376	Use of antiretroviral drugs to prevent the transmission and acquisition of HIV. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 544-545.	0.2	0
377	Qualitative Insights Into Adherence to HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Gay and Bisexual Men. <i>AIDS Patient Care and STDs</i> , 2018, 32, 519-528.	1.1	10
378	Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. <i>PLoS ONE</i> , 2018, 13, e0208107.	1.1	79
379	Going global: the adoption of the World Health Organization’s enabling recommendation on oral pre-exposure prophylaxis for HIV. <i>Sexual Health</i> , 2018, 15, 489.	0.4	52
380	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. <i>HIV Clinical Trials</i> , 2018, 19, 129-138.	2.0	51
381	PrEP Continuation, HIV and STI Testing Rates, and Delivery of Preventive Care in a Clinic-Based Cohort. <i>AIDS Education and Prevention</i> , 2018, 30, 393-405.	0.6	25
382	Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. <i>Hepatology, Medicine and Policy</i> , 2018, 3, 12.	1.7	22
383	Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. <i>Sexual Health</i> , 2018, 15, 542.	0.4	88
384	Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. <i>PLoS Medicine</i> , 2018, 15, e1002655.	3.9	27
385	Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosis. <i>BMC Infectious Diseases</i> , 2018, 18, 531.	1.3	15
386	Pre-exposure prophylaxis among men who have sex with men in the Amsterdam Cohort Studies: Use, eligibility, and intention to use. <i>PLoS ONE</i> , 2018, 13, e0205663.	1.1	27

#	ARTICLE	IF	CITATIONS
387	Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice. <i>The Open Virology Journal</i> , 2018, 12, 1-13.	1.8	11
388	The estimated number of potential PrEP users among gay-identifying men who have sex with men in Australia. <i>PLoS ONE</i> , 2018, 13, e0204138.	1.1	6
389	Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017. <i>PLoS ONE</i> , 2018, 13, e0204738.	1.1	23
390	Knowledge and use of HIV pre-exposure prophylaxis among men who have sex with men in Berlin – A multicentre, cross-sectional survey. <i>PLoS ONE</i> , 2018, 13, e0204067.	1.1	22
391	Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal. <i>Journal of the International AIDS Society</i> , 2018, 21, e25126.	1.2	30
392	Response Rates of Medical Providers to Internet Surveys Regarding Their Adoption of Preexposure Prophylaxis for HIV: Methodological Implications. <i>Journal of the International Association of Providers of AIDS Care</i> , 2018, 17, 232595821879837.	0.6	25
393	Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 799.	1.6	51
394	Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 34942-34953.	4.0	32
395	Lessons from a decade of voluntary medical male circumcision implementation and their application to HIV pre-exposure prophylaxis scale up. <i>International Journal of STD and AIDS</i> , 2018, 29, 1432-1443.	0.5	13
396	HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1082-1097.	2.3	21
397	Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. <i>Aids</i> , 2018, 32, 2353-2361.	1.0	10
398	Disclosure of Same-Sex Behaviors to Health-care Providers and Uptake of HIV Testing for Men Who Have Sex With Men: A Systematic Review. <i>American Journal of Men's Health</i> , 2018, 12, 1197-1214.	0.7	66
399	Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women. <i>AIDS and Behavior</i> , 2018, 22, 3044-3056.	1.4	78
400	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 412-424.	8.2	62
401	Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1180-1190.	3.0	7
402	Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics. <i>HIV Medicine</i> , 2018, 19, 485-490.	1.0	92
403	Response to the Hammoud et al paper on “the new MTV generation”. <i>International Journal of Drug Policy</i> , 2018, 55, 205-206.	1.6	2
404	Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use. <i>Aids</i> , 2018, 32, 1527-1532.	1.0	62

#	ARTICLE	IF	CITATIONS
405	HIV PrEP in the Military: Experience at a Tertiary Care Military Medical Center. <i>Military Medicine</i> , 2018, 183, 445-449.	0.4	11
406	Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities. <i>AIDS and Behavior</i> , 2018, 22, 3071-3082.	1.4	31
407	Medical students reflect on the future of Pre-Exposure Prophylaxis use among adolescents and young adults. <i>Preventive Medicine</i> , 2018, 113, 122-123.	1.6	2
408	Designing a brief behaviour change intervention to reduce sexually transmitted infections: a discrete choice experiment. <i>International Journal of STD and AIDS</i> , 2018, 29, 851-860.	0.5	5
409	The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. <i>Annals of Epidemiology</i> , 2018, 28, 841-849.	0.9	295
410	Advancing independent adolescent consent for participation in HIV prevention research. <i>Journal of Medical Ethics</i> , 2018, 44, 431-433.	1.0	9
411	Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017. <i>Annals of Epidemiology</i> , 2018, 28, 833-840.	0.9	168
412	Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2018, 67, 962-964.	2.9	35
413	HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia. <i>Current HIV/AIDS Reports</i> , 2018, 15, 308-314.	1.1	5
414	Towards elimination of HIV transmission, AIDS and HIV-related deaths in the UK. <i>HIV Medicine</i> , 2018, 19, 505-512.	1.0	45
415	Understanding willingness to use oral pre-exposure prophylaxis for HIV prevention among men who have sex with men in China. <i>PLoS ONE</i> , 2018, 13, e0199525.	1.1	21
416	Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. <i>Frontiers in Public Health</i> , 2018, 6, 195.	1.3	33
417	Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives. <i>Water Research</i> , 2018, 145, 231-247.	5.3	84
418	The Acceptability of Pre-Exposure Prophylaxis: Beliefs of Health-Care Professionals Working in Sexually Transmitted Infections Clinics and HIV Treatment Centers. <i>Frontiers in Public Health</i> , 2018, 6, 5.	1.3	15
419	HIV Prevention After Discontinuing Pre-Exposure Prophylaxis: Conclusions From a Case Study. <i>Frontiers in Public Health</i> , 2018, 6, 137.	1.3	8
420	Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study. <i>Frontiers in Public Health</i> , 2018, 6, 151.	1.3	35
421	HIV testing history and access to treatment among migrants living with HIV in Europe. <i>Journal of the International AIDS Society</i> , 2018, 21, e25123.	1.2	27
422	HIV. <i>Lancet</i> , The, 2018, 392, 685-697.	6.3	219

#	ARTICLE	IF	CITATIONS
423	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA - Journal of the American Medical Association, 2018, 320, 379.	3.8	486
424	Interest in <sc>HIV</sc> pre-exposure prophylaxis in men who have sex with men in West Africa (Coh<sc>MSM ANRS</sc> 12324 " Expertise France). Tropical Medicine and International Health, 2018, 23, 1084-1091.	1.0	15
425	Expert consensus statement on the science of <sc>HIV</sc> in the context of criminal law. Journal of the International AIDS Society, 2018, 21, e25161.	1.2	59
426	Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. PLoS Computational Biology, 2018, 14, e1006155.	1.5	19
428	PCR-based rapid diagnostic tests as a strategy for preventing infections with sexually transmitted diseases-a "diagnostics-as-prevention" modelling approach. Letters in Applied Microbiology, 2018, 67, 420-424.	1.0	6
429	How to do it: setting up a PrEP service in an integrated sexual reproductive health service setting. Sexually Transmitted Infections, 2018, 94, 327-330.	0.8	3
430	Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV, 2018, 5, e438-e447.	2.1	337
431	<sc>HIV</sc> health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (<sc>ECEE</sc>) Network Group. HIV Medicine, 2018, 19, 629-633.	1.0	8
432	PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States. Journal of the Association of Nurses in AIDS Care, 2018, 29, 835-848.	0.4	48
433	Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?. Drugs and Aging, 2018, 35, 485-491.	1.3	16
434	Poppers and PrEP: Use of Pre-exposure Prophylaxis Among Men Who Have Sex with Men Who Use Inhaled Nitrites. AIDS and Behavior, 2018, 22, 3658-3672.	1.4	19
435	Seroconversion on preexposure prophylaxis. Aids, 2018, 32, 1199-1200.	1.0	0
436	The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco. BMC Medicine, 2018, 16, 58.	2.3	25
437	Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial. Clinical Infectious Diseases, 2018, 67, 1847-1852.	2.9	9
438	Cabotegravir. Current Opinion in HIV and AIDS, 2018, 13, 334-340.	1.5	14
439	The intention to use HIV-pre-exposure prophylaxis (PrEP) among men who have sex with men in Switzerland: testing an extended explanatory model drawing on the unified theory of acceptance and use of technology (LUTAUT). Zeitschrift Fur Gesundheitswissenschaften, 2018, 26, 247-259.	0.8	7
440	Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clinical Infectious Diseases, 2018, 66, 1566-1572.	2.9	77
441	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS Research and Human Retroviruses, 2018, 34, 645-656.	0.5	23

#	ARTICLE	IF	CITATIONS
442	DIY HIV prevention: Formative qualitative research with men who have sex with men who source PrEP outside of clinical trials. <i>PLoS ONE</i> , 2018, 13, e0202830.	1.1	21
443	Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States. <i>Annals of Epidemiology</i> , 2018, 28, 830-832.	0.9	13
444	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2018, 286, 315-325.	4.8	66
445	Behavioural and demographic correlates of undiagnosed HIV infection in a MSM sample recruited in 13 European cities. <i>BMC Infectious Diseases</i> , 2018, 18, 368.	1.3	15
446	Sexual behaviours and sexually transmitted infection outcomes in a cohort of HIV-negative men who have sex with men attending sexual health clinics in England. <i>International Journal of STD and AIDS</i> , 2018, 29, 1407-1416.	0.5	3
447	Lessons learned from the experiences of informal PrEP users in France: results from the ANRS-PrEPAGE study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 48-53.	0.6	14
448	Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. <i>Lancet HIV</i> , 2018, 5, e498-e505.	2.1	37
449	Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0191251.	1.1	37
450	Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-2017. <i>Lancet HIV</i> , 2018, 5, e448-e456.	2.1	145
451	The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents. <i>Lancet HIV</i> , 2018, 5, e329-e334.	2.1	22
452	Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement. <i>PLoS Medicine</i> , 2018, 15, e1002485.	3.9	20
453	Profilaxis preexposici3n al VIH en Espa3a: situaci3n pol3tica y administrativa. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2019, 37, 656-660.	0.3	4
454	Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting. <i>AIDS and Behavior</i> , 2019, 23, 548-555.	1.4	101
455	Factors Associated with Sexual Risks and Risk of STIs, HIV and Other Blood-Borne Viruses Among Women Using Heroin and Other Drugs: A Systematic Literature Review. <i>AIDS and Behavior</i> , 2019, 23, 222-251.	1.4	21
456	Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. <i>AIDS and Behavior</i> , 2019, 23, 190-200.	1.4	19
457	Preexposure prophylaxis comprehension and the certainty of willingness to use preexposure prophylaxis among men who have sex with men in China. <i>International Journal of STD and AIDS</i> , 2019, 30, 4-11.	0.5	17
458	Public Health Detailing for Human Immunodeficiency Virus Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2019, 68, 860-864.	2.9	22
459	Empowerment Evaluation: A Case Study of Citywide Implementation Within an HIV Prevention Context. <i>American Journal of Evaluation</i> , 2019, 40, 318-334.	0.6	5

#	ARTICLE	IF	CITATIONS
460	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	1.1	58
461	What Motivates Gay and Bisexual Men to Participate in PrEP-Related Research?. <i>International Journal of Sexual Health</i> , 2019, 31, 283-290.	1.2	7
462	Medicaid Expansion, HIV Testing, and HIV-Related Risk Behaviors in the United States, 2010–2017. <i>American Journal of Public Health</i> , 2019, 109, 1404-1412.	1.5	18
463	Use and Acceptability of HIV Self-Testing Among First-Time Testers at Risk for HIV in Senegal. <i>AIDS and Behavior</i> , 2019, 23, 130-141.	1.4	35
464	Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa. <i>BMC Public Health</i> , 2019, 19, 996.	1.2	14
465	Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. <i>PLoS ONE</i> , 2019, 14, e0221281.	1.1	24
466	Are current guidelines adapted for patient eligibility to PrEP? A case report. <i>BMC Infectious Diseases</i> , 2019, 19, 601.	1.3	1
467	Pre-exposure prophylaxis access in federally qualified health centers across 11 United States metropolitan statistical areas. <i>International Journal of STD and AIDS</i> , 2019, 30, 978-984.	0.5	11
468	HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya. <i>Trials</i> , 2019, 20, 396.	0.7	20
469	Incidence of cutaneous adverse events after exposure to tenofovir/emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e470-e471.	1.3	1
470	Using HIV Risk Prediction Tools to Identify Candidates for Pre-Exposure Prophylaxis: Perspectives from Patients and Primary Care Providers. <i>AIDS Patient Care and STDs</i> , 2019, 33, 372-378.	1.1	21
471	Antiretroviral Medications for the Prevention of HIV Infection. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 629-646.	1.9	6
472	Gender-based violence and engagement in biomedical HIV prevention, care and treatment: a scoping review. <i>BMC Public Health</i> , 2019, 19, 897.	1.2	68
473	Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). <i>Pharmaceutics</i> , 2019, 11, 315.	2.0	62
474	Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. <i>PLoS ONE</i> , 2019, 14, e0219802.	1.1	3
475	Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1599.	2.2	14
476	Facilitating engagement with PrEP and other HIV prevention technologies through practice-based combination prevention. <i>Journal of the International AIDS Society</i> , 2019, 22, e25294.	1.2	17
477	Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure. <i>Frontiers in Pharmacology</i> , 2019, 10, 721.	1.6	28

#	ARTICLE	IF	CITATIONS
478	HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. <i>Journal of the International AIDS Society</i> , 2019, 22, e25298.	1.2	150
479	Geographic Access to Preexposure Prophylaxis Clinics Among Men Who Have Sex With Men in the United States. <i>American Journal of Public Health</i> , 2019, 109, 1216-1223.	1.5	82
480	Location of Pre-exposure Prophylaxis Services Across New York City Neighborhoods: Do Neighborhood Socio-demographic Characteristics and HIV Incidence Matter?. <i>AIDS and Behavior</i> , 2019, 23, 2795-2802.	1.4	6
481	Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	1
482	Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study. <i>BMC Infectious Diseases</i> , 2019, 19, 663.	1.3	10
483	Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. <i>PLoS ONE</i> , 2019, 14, e0218710.	1.1	10
484	NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand. <i>BMJ Open</i> , 2019, 9, e026363.	0.8	6
485	Cohort profile: Actual Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada. <i>BMJ Open</i> , 2019, 9, e028768.	0.8	40
486	Pre-Exposure Prophylaxis Counseling in a Community Sexual Health Clinic for Men Who Have Sex with Men in Lisbon, Portugal. <i>Acta Medica Portuguesa</i> , 2019, 32, 441.	0.2	4
487	Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. <i>Journal of the International AIDS Society</i> , 2019, 22, e25355.	1.2	85
488	Attitudes and referral practices for pre-exposure prophylaxis (PrEP) among HIV rapid testers and case managers in Philadelphia: A mixed methods study. <i>PLoS ONE</i> , 2019, 14, e0223486.	1.1	4
489	HIV pre-exposure prophylaxis (PrEP) in Spain: Political and administrative situation. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019, 37, 656-660.	0.2	2
490	Give PrEP a chance: moving on from the 'risk compensation' concept. <i>Journal of the International AIDS Society</i> , 2019, 22, e25351.	1.2	57
491	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2019, 22, e25381.	1.2	13
492	Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis – a qualitative analysis. <i>Journal of the International AIDS Society</i> , 2019, 22, e25389.	1.2	42
493	The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward. <i>Journal of the International AIDS Society</i> , 2019, 22, e25390.	1.2	24
494	Drogue et sexualité gay sous influence: «Quand on prend ça, c'est fait pour». <i>Sexologies</i> , 2019, 28, 128-134.	0.5	0
496	«Getting high to get laid.» Drugs and gay sex under influence.. <i>Sexologies</i> , 2019, 28, e48-e53.	0.5	5

#	ARTICLE	IF	CITATIONS
497	Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. <i>Journal of the International AIDS Society</i> , 2019, 22, e25407.	1.2	82
498	Next-Generation HIV Pre-Exposure Prophylaxis Preferences Among Men Who Have Sex with Men Taking Daily Oral Pre-Exposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2019, 33, 482-491.	1.1	19
499	Global implementation of PrEP for HIV prevention: setting expectations for impact. <i>Journal of the International AIDS Society</i> , 2019, 22, e25370.	1.2	45
500	Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). <i>Journal of the International AIDS Society</i> , 2019, 22, e25408.	1.2	33
502	Why we need pre-exposure prophylaxis: incident HIV and syphilis among men, and transgender women, who have sex with men, Bangkok, Thailand, 2005-2015. <i>International Journal of STD and AIDS</i> , 2019, 30, 430-439.	0.5	22
503	High Prevalence of Anal and Oral High-Risk Human Papillomavirus in Human Immunodeficiency Virus-Uninfected French Men Who Have Sex With Men and Use Preexposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz291.	0.4	17
504	Impact of HIV risk perception on both pre-exposure prophylaxis and condom use. <i>Journal of Health Psychology</i> , 2021, 26, 1575-1586.	1.3	11
506	Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program. <i>Sexual Health</i> , 2019, 16, 180-186.	0.4	12
507	Sex partners as bystanders in HIV prevention trials: Two test cases for research ethics. <i>Clinical Trials</i> , 2019, 16, 455-457.	0.7	0
508	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. <i>PLoS ONE</i> , 2019, 14, e0222183.	1.1	1
509	Advancing Novel PrEP Products – Alternatives to Non-Inferiority. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	7
510	Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 6231-6247.	3.3	16
511	HIV control strategies for sex worker-client contact networks. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20190497.	1.5	1
512	Barriers to PrEP uptake: Perspectives of community health workers in the Mid-South region of the United States. <i>Journal of HIV/AIDS and Social Services</i> , 2019, 18, 295-312.	0.7	4
513	Decisional Balance and Contemplation Ladder to Support Interventions for HIV Pre-Exposure Prophylaxis Uptake and Persistence. <i>AIDS Patient Care and STDs</i> , 2019, 33, 67-78.	1.1	11
514	Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service. <i>PLoS ONE</i> , 2019, 14, e0210106.	1.1	14
515	The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e127-e136.	4.7	21
517	Prevention and treatment of sexually transmitted infections in high-risk individuals, including patients with HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 117-126.	0.2	4

#	ARTICLE	IF	CITATIONS
518	Accompagnement médical et communautaire dans un essai de prévention biomédicale: vers une nouvelle forme d'éducation?. <i>Pratiques Psychologiques</i> , 2019, 25, 367-381.	0.4	0
519	2-Hydroxypropyl- β -cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2019, 306, 89-96.	4.8	49
520	First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2752-2758.	1.3	20
521	Global dynamics and cost-effectiveness analysis of HIV pre-exposure prophylaxis and structured treatment interruptions based on a multi-scale model. <i>Applied Mathematical Modelling</i> , 2019, 75, 162-200.	2.2	10
522	Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. <i>PLoS ONE</i> , 2019, 14, e0214151.	1.1	48
523	Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPREP: 2 year results from a demonstration study. <i>Lancet HIV</i> , 2019, 6, e447-e455.	2.1	114
524	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2214.	3.8	172
525	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2203.	3.8	219
526	Confronting Rising STIs in the Era of PrEP and Treatment as Prevention. <i>Current HIV/AIDS Reports</i> , 2019, 16, 244-256.	1.1	47
527	Mapping the study topics and characteristics of HIV pre-exposure prophylaxis research literature: a protocol for a scoping review. <i>BMJ Open</i> , 2019, 9, e024212.	0.8	3
528	Summary of German/Austrian HIV PrEP guideline. <i>HIV Medicine</i> , 2019, 20, 368-376.	1.0	11
529	Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain. <i>Frontiers in Microbiology</i> , 2019, 10, 655.	1.5	31
530	A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 794-804.	0.5	5
531	Enhancing national prevention and treatment services for sex workers in Zimbabwe: a process evaluation of the SAPPH-IRE trial. <i>Health Policy and Planning</i> , 2019, 34, 337-345.	1.0	8
532	A Randomized Study of Passive versus Active PrEP Patient Navigation for a Heterogeneous Population at Risk for HIV in South Florida. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821984884.	0.6	27
533	The Pre-exposure Prophylaxis (PrEP) Continuum of Care and Correlates to Initiation Among HIV-Negative Men Recruited at Miami Gay Pride 2018. <i>Journal of Urban Health</i> , 2019, 96, 835-844.	1.8	13
534	Modeling the joint effects of adolescent and adult PrEP for sexual minority males in the United States. <i>PLoS ONE</i> , 2019, 14, e0217315.	1.1	10
535	Interest in Pre-exposure Prophylaxis (PrEP) for HIV is Limited Among Women in a General Obstetrics & Gynecology Setting. <i>AIDS and Behavior</i> , 2019, 23, 2741-2748.	1.4	20

#	ARTICLE	IF	CITATIONS
536	Preparing for PrEP: estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have sex with men in England. <i>Sexually Transmitted Infections</i> , 2019, 95, 484-487.	0.8	7
537	Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet. <i>International Journal of STD and AIDS</i> , 2019, 30, 765-768.	0.5	4
538	The new face of HIV. <i>InnovAiT</i> , 2019, 12, 361-368.	0.0	0
539	Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color. <i>AIDS and Behavior</i> , 2019, 23, 2719-2729.	1.4	85
540	The Attitudes toward Pre-Exposure Prophylaxis (PrEP) Scale: Development and validation. <i>Journal of HIV/AIDS and Social Services</i> , 2019, 18, 197-205.	0.7	4
541	Having children outside a heterosexual relationship: options for persons living with HIV. <i>Sexually Transmitted Infections</i> , 2019, 95, 99-101.	0.8	4
542	HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1234-1240.	0.6	29
543	Implementing pre-exposure prophylaxis could prevent most new HIV infections in transsexual women and men who have sex with men. <i>Revista Colombiana de Psicología</i> , 2019, 219, 360-366.	0.3	2
544	Impact of sexual trajectories of men who have sex with men on the reduction in HIV transmission by pre-exposure prophylaxis. <i>Epidemics</i> , 2019, 28, 100337.	1.5	6
545	Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial. <i>BMC Public Health</i> , 2019, 19, 431.	1.2	50
546	Current and emerging therapies to combat persistent intracellular pathogens. <i>Current Opinion in Pharmacology</i> , 2019, 48, 33-39.	1.7	9
547	Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. <i>Pharmaceuticals</i> , 2019, 12, 62.	1.7	30
548	A Cross-sectional Survey of Internal Medicine Resident Knowledge, Attitudes, Behaviors, and Experiences Regarding Pre-Exposure Prophylaxis for HIV Infection. <i>Journal of General Internal Medicine</i> , 2019, 34, 1258-1278.	1.3	18
549	HIV prevalence, spatial distribution and risk factors for HIV infection in the Kenyan fishing communities of Lake Victoria. <i>PLoS ONE</i> , 2019, 14, e0214360.	1.1	21
550	Contrasting Self-Perceived Need and Guideline-Based Indication for HIV Pre-Exposure Prophylaxis Among Young, Black Men Who Have Sex with Men Offered Pre-Exposure Prophylaxis in Atlanta, Georgia. <i>AIDS Patient Care and STDs</i> , 2019, 33, 112-119.	1.1	31
551	Public Awareness of HIV Pre-Exposure Prophylaxis in Durham, North Carolina. <i>North Carolina Medical Journal</i> , 2019, 80, 7-11.	0.1	3
552	What are the motivations and barriers to pre-exposure prophylaxis (PrEP) use among black men who have sex with men aged 18-45 in London? Results from a qualitative study. <i>Sexually Transmitted Infections</i> , 2019, 95, 262-266.	0.8	29
553	Improvements in the HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078. <i>Journal of the International AIDS Society</i> , 2019, 22, e25246.	1.2	14

#	ARTICLE	IF	CITATIONS
554	Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2019, 220, S16-S18.	1.9	13
555	BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. <i>HIV Medicine</i> , 2019, 20, s2-s80.	1.0	30
556	Moving Metaphors: Shifting Institutional Responsibilities and Evidentiary Boundaries in the Commissioning of Pre-Exposure Prophylaxis for HIV. <i>Qualitative Health Research</i> , 2019, 29, 1408-1418.	1.0	2
557	Clusters of Sexual Behavior in Human Immunodeficiency Virus-positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. <i>Clinical Infectious Diseases</i> , 2019, 70, 416-424.	2.9	9
558	Tenofovir and emtricitabine resistance among antiretroviral-naïve patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019, 24, 211-220.	0.6	2
559	Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1380.	3.8	266
560	Generalizing from the results of randomized studies of treatment: Can non-randomized studies be of help?. <i>European Journal of Epidemiology</i> , 2019, 34, 715-718.	2.5	10
561	Drug Resistance During HIV Pre-Exposure Prophylaxis. <i>Drugs</i> , 2019, 79, 609-619.	4.9	54
562	The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 199.	1.6	14
563	Training health care providers to provide PrEP for HIV serodiscordant couples attending public health facilities in Kenya. <i>Global Public Health</i> , 2019, 14, 1524-1534.	1.0	12
564	Barriers to HIV pre-exposure prophylaxis among African, Caribbean and Black men in Toronto, Canada. <i>PLoS ONE</i> , 2019, 14, e0213740.	1.1	15
565	Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial. <i>Sexually Transmitted Infections</i> , 2019, 95, 449-454.	0.8	14
566	Planning area-specific prevention and intervention programs for HIV using spatial regression analysis. <i>Public Health</i> , 2019, 169, 41-49.	1.4	7
567	Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives. <i>Journal of General Internal Medicine</i> , 2019, 34, 535-543.	1.3	18
568	HIV Prevention Interventions for Adolescents. <i>Current HIV/AIDS Reports</i> , 2019, 16, 120-128.	1.1	66
569	Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. <i>Journal of the International AIDS Society</i> , 2019, 22, e25250.	1.2	74
570	Lymphogranuloma venereum presenting as penile ulcer in two HIV-negative gay men. <i>International Journal of STD and AIDS</i> , 2019, 30, 515-518.	0.5	2
571	Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. <i>PLoS Computational Biology</i> , 2019, 15, e1006740.	1.5	21

#	ARTICLE	IF	CITATIONS
572	Use of, and likelihood of using, HIV pre-exposure prophylaxis among men who have sex with men in Europe and Central Asia: findings from a 2017 large geosocial networking application survey. <i>Sexually Transmitted Infections</i> , 2019, 95, 187-192.	0.8	29
573	Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25252.	1.2	99
574	Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (<scp>MSM</scp>) in three US cities: results from the <scp>HPTN</scp> 073 study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25223.	1.2	81
575	â€œLittle Tablets of Goldâ€: An Examination of the Psychological and Social Dimensions of PrEP Among LGBTQ Communities. <i>AIDS Education and Prevention</i> , 2019, 31, 51-62.	0.6	16
576	PrEP in Prisons: HIV prevention in incarcerated populations. <i>International Journal of Prisoner Health</i> , 2019, 16, 199-206.	0.5	5
577	Effect of â€˜lifestyle stigmaâ€™ on public support for NHS-provisioned pre-exposure prophylaxis (PrEP) and preventative interventions for HPV and type 2 diabetes: a nationwide UK survey. <i>BMJ Open</i> , 2019, 9, e029747.	0.8	10
578	Diversification of the prevention of sexually transmitted infections. <i>Future Microbiology</i> , 2019, 14, 1465-1468.	1.0	7
579	Ten Things We Need to Do to Achieve the Goals of the End the HIV Epidemic Plan for America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, S94-S98.	0.9	12
580	Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants. <i>International Journal of Drug Policy</i> , 2019, 74, 246-254.	1.6	30
581	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
582	Audit of patient retention in pre-exposure prophylaxis (PrEP) services in an integrated sexual reproductive health service setting. <i>International Journal of STD and AIDS</i> , 2019, 30, 1432-1435.	0.5	4
583	Differences Between Groups of Pre-exposure Prophylaxis (PrEP) Using Couples in HIV-Negative/Unknown Relationships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 419-428.	0.9	9
584	Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis. <i>BMJ Open</i> , 2019, 9, e031085.	0.8	6
585	Prepared for PrEP: preferences for HIV pre-exposure prophylaxis among Chinese men who have sex with men in an online national survey. <i>BMC Infectious Diseases</i> , 2019, 19, 1057.	1.3	7
586	Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. <i>Journal of the International AIDS Society</i> , 2019, 22, e25419.	1.2	49
587	HIV Pre-Exposure Prophylaxis Implementation Cascade Among Health Care Professionals in the United States: Implications from a Systematic Review and Meta-Analysis. <i>AIDS Patient Care and STDs</i> , 2019, 33, 507-527.	1.1	75
588	Is reaching 90â€“90â€“90 enough to end AIDS? Lessons from Amsterdam. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 455-463.	1.5	10
589	PrEParing to End the HIV Epidemic â€” Californiaâ€™s Route as a Road Map for the United States. <i>New England Journal of Medicine</i> , 2019, 381, 2489-2491.	13.9	28

#	ARTICLE	IF	CITATIONS
590	“You can smell the freedom”: a qualitative study on perceptions and experiences of sex among Swedish men who have sex with men in Berlin. <i>BMJ Open</i> , 2019, 9, e024459.	0.8	6
591	Unspeakable PrEP: a qualitative study of sexual communication, problematic integration, and uncertainty management among men who have sex with men in Taiwan. <i>Journal of Applied Communication Research</i> , 2019, 47, 611-627.	0.7	9
592	Transformation of Australian Community Pharmacies Into Good Clinical Practice Compliant Trial Pharmacies for HIV Pre-Exposure Prophylaxis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1269.	1.6	2
593	Global Challenges to Human Immunodeficiency Virus Prevention. <i>Health Care Manager</i> , 2019, 38, 74-81.	1.4	1
594	Behavioral Interventions to Enhance PrEP Uptake Among Black Men Who Have Sex With Men. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 151-163.	0.4	18
595	Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners. <i>Medicine (United States)</i> , 2019, 98, e18232.	0.4	3
596	Comprehensive HIV risk reduction interventions for 2020 and beyond. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 423-432.	1.5	16
597	“This is mine, this is for me”. <i>Aids</i> , 2019, 33, S45-S52.	1.0	22
598	Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. <i>Aids</i> , 2019, 33, 2189-2195.	1.0	55
599	Comfort Discussing HIV Pre-exposure Prophylaxis With Patients Among Physicians in an Urban Emergency Department. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e49-e52.	0.9	7
600	Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 276-283.	0.9	20
601	Brief Report: Changes in Behavior After PrEP Initiation Among Australian Gay and Bisexual Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 52-56.	0.9	24
602	Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 406-413.	0.9	11
603	Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 516-520.	0.9	1
604	Regulatory Perspectives for Streamlining HIV Prevention Trials. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	4
605	Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. <i>Medicine (United States)</i> , 2019, 98, e17716.	0.4	25
606	HIV Seroconversion in the Era of Pharmacologic Prevention: A Case–Control Study at a San Francisco STD Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 159-165.	0.9	7
607	Mapping the Study Characteristics and Topics of HIV Pre-Exposure Prophylaxis Research Literature: A Scoping Review. <i>AIDS Education and Prevention</i> , 2019, 31, 505-522.	0.6	4

#	ARTICLE	IF	CITATIONS
608	STD Partner Services to Monitor and Promote HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 533-541.	0.9	32
609	Brief Report: Quantitative Assessment of Brief Messages About HIV Pre-exposure Prophylaxis Among HIV-Infected and HIV-Uninfected Black/African American and Hispanic/Latino MSM. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 31-35.	0.9	7
610	Gonorrhoea. <i>Nature Reviews Disease Primers</i> , 2019, 5, 79.	18.1	284
611	PrEP-RN. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 301-311.	0.4	33
612	PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, S113-S117.	0.9	19
613	Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 551-558.	0.9	24
614	Current and Future Challenges in Trial Design for Pre-Exposure Prophylaxis in HIV Prevention. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
615	Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA Network Open</i> , 2019, 2, e1917134.	2.8	102
616	Pre-exposure Prophylaxis Use and Medication Adherence Among Men Who Have Sex With Men. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, e38-e61.	0.4	35
617	Differences in sexually transmitted infection risk comparing preexposure prophylaxis users and propensity score matched historical controls in a clinic setting. <i>Aids</i> , 2019, 33, 1773-1780.	1.0	16
618	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 78-82.	0.9	18
619	Implementing Pre-exposure Prophylaxis for HIV Prevention at an Urban Youth Clinic. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 232-237.	0.4	2
620	Relationship between self-efficacy and HIV testing uptake among young men who have sex with men in Myanmar: a cross-sectional analysis. <i>International Journal of STD and AIDS</i> , 2019, 30, 20-28.	0.5	7
621	Risk Perception and Interest in HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men with Rectal Gonorrhoea and Chlamydia Infection. <i>Archives of Sexual Behavior</i> , 2019, 48, 1185-1190.	1.2	21
622	A structural equation model to predict pre-exposure prophylaxis acceptability in men who have sex with men in Leicester, UK. <i>HIV Medicine</i> , 2019, 20, 11-18.	1.0	12
623	Mind Matters: Treatment Concerns Predict the Emergence of Antiretroviral Therapy Side Effects in People with HIV. <i>AIDS and Behavior</i> , 2019, 23, 489-498.	1.4	6
624	Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 1904-1916.	1.4	69
625	High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports. <i>Sexual Health</i> , 2019, 16, 80.	0.4	19

#	ARTICLE	IF	CITATIONS
626	Sexual safety and HIV prevention in travel medicine: Practical considerations and new approaches. <i>Travel Medicine and Infectious Disease</i> , 2019, 28, 68-73.	1.5	9
627	Stigma, the Media, and Pre-exposure Prophylaxis for HIV Prevention: Observations for Enhancing Knowledge Translation and Resisting Stigma in the Canadian Context. <i>AIDS and Behavior</i> , 2019, 23, 1877-1887.	1.4	15
628	Cancer and AIDS. , 2019, , .		0
629	Network Modeling of PrEP Uptake on Referral Networks and Health Venue Utilization Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 1698-1707.	1.4	11
630	Is HIV prevention creating new biosocialities among gay men? Treatment as prevention and pre-exposure prophylaxis in Canada. <i>Sociology of Health and Illness</i> , 2019, 41, 484-501.	1.1	29
631	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246.	1.0	17
632	HIV Both Starts and Stops with Me™: Configuring the Neoliberal Sexual Actor in HIV Prevention. <i>Sexuality and Culture</i> , 2019, 23, 657-673.	1.1	6
633	The Traveler With HIV. , 2019, , 279-286.		0
634	Prevalencia y tratamiento de las infecciones de transmisión sexual en personas con alto riesgo, incluyendo pacientes infectados por el VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 117-126.	0.3	8
635	Adolescent Preexposure Prophylaxis Administration: An Education Curriculum for Health Care Providers. <i>Journal of Pediatric Health Care</i> , 2019, 33, 288-295.	0.6	8
636	The non-positive antiretroviral gay body: the biomedicalisation of gay sex in England. <i>Culture, Health and Sexuality</i> , 2019, 21, 1117-1130.	1.0	15
637	Incidence and Correlates of Sexually Transmitted Infections Among Black Men Who Have Sex With Men Participating in the HIV Prevention Trials Network 073 Preexposure Prophylaxis Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1597-1604.	2.9	27
638	Enhanced surveillance of syphilis cases among men who have sex with men in London, October 2016–January 2017. <i>International Journal of STD and AIDS</i> , 2019, 30, 422-429.	0.5	5
639	Long-Acting HIV Drugs for Treatment and Prevention. <i>Annual Review of Medicine</i> , 2019, 70, 137-150.	5.0	87
640	The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour. <i>AIDS and Behavior</i> , 2019, 23, 1708-1720.	1.4	56
641	A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States. <i>AIDS and Behavior</i> , 2019, 23, 1749-1770.	1.4	31
642	High subsequent and recurrent sexually transmitted infection prevalence among newly diagnosed HIV-positive Thai men who have sex with men and transgender women in the Test and Treat cohort. <i>International Journal of STD and AIDS</i> , 2019, 30, 140-146.	0.5	15
643	Towards an Integration of PrEP into a Safe Sex Ethics Framework for Men Who Have Sex with Men. <i>Public Health Ethics</i> , 2019, 12, 54-63.	0.4	9

#	ARTICLE	IF	CITATIONS
644	Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. <i>AIDS and Behavior</i> , 2019, 23, 1287-1296.	1.4	14
645	Trends in Attitudes to and the Use of HIV Pre-exposure Prophylaxis by Australian Gay and Bisexual Men, 2011-2017: Implications for Further Implementation from a Diffusion of Innovations Perspective. <i>AIDS and Behavior</i> , 2019, 23, 1939-1950.	1.4	47
646	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50.	2.1	43
647	Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2010-2017.	2.9	96
648	High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE. <i>AIDS and Behavior</i> , 2019, 23, 1780-1789.	1.4	30
650	Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. <i>Clinical Infectious Diseases</i> , 2019, 68, 1129-1135.	2.9	14
651	Perceived Candidacy for Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men in Paris, France. <i>AIDS and Behavior</i> , 2019, 23, 1771-1779.	1.4	9
652	Considerable interest in pre-exposure prophylaxis uptake among men who have sex with men recruited from a popular geosocial-networking smartphone application in London. <i>Global Public Health</i> , 2019, 14, 112-121.	1.0	11
653	Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 3-10.	2.0	40
654	Transactional Sex and Preferences for Pre-Exposure Prophylaxis (PrEP) Administration Modalities Among Men Who Have Sex With Men (MSM). <i>Journal of Sex Research</i> , 2019, 56, 650-658.	1.6	9
655	Capturing public interest toward new tools for controlling human immunodeficiency virus (HIV) infection exploiting data from Google Trends. <i>Health Informatics Journal</i> , 2019, 25, 1383-1397.	1.1	20
656	Problematizing the Discourse of "Post-AIDS". <i>Journal of Medical Humanities</i> , 2020, 41, 95-105.	0.3	6
657	Assessing Mozambicans' willingness and determinants to use pre-exposure prophylactic HIV medication. <i>Journal of Health Psychology</i> , 2020, 25, 1954-1964.	1.3	5
658	Correlations Between Human Immunodeficiency Virus (HIV) Infection and Rectal Gonorrhea Incidence in Men Who Have Sex With Men: Implications for Future HIV Preexposure Prophylaxis Trials. <i>Journal of Infectious Diseases</i> , 2020, 221, 214-217.	1.9	25
659	Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents. <i>Journal of Infectious Diseases</i> , 2020, 221, 172-174.	1.9	1
660	Open pilot trial of a brief motivational interviewing-based HIV pre-exposure prophylaxis intervention for men who have sex with men: preliminary effects, and evidence of feasibility and acceptability. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 406-410.	0.6	13
661	Acceptability of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in Benin: a qualitative study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 242-248.	0.6	7
662	Misclassification of sexual health risks in a self-identified low risk cohort of men who have sex with men (MSM) enrolled in a community based PrEP program. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 230-237.	0.6	11

#	ARTICLE	IF	CITATIONS
663	The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. <i>Clinical Infectious Diseases</i> , 2020, 70, 633-642.	2.9	20
664	Social Identity and Attitudes toward HIV Pre-exposure Prophylaxis: A Structural Equation Model. <i>Journal of Social Service Research</i> , 2020, 46, 331-344.	0.7	4
665	Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 1-10.	1.5	16
666	What do we say about condoms in 2019?. <i>Lancet HIV</i> , 2020, 7, e82-e83.	2.1	0
667	Do Try To Use Condoms, But Knowledge and Interest in PrEP Among Male Sex Workers in Mexico City. <i>Archives of Sexual Behavior</i> , 2020, 49, 355-363.	1.2	13
668	Combined Sexual Behavioral Profiles in HIV-Seronegative Men Who have Sex with Men in West Africa (CohMSM ANRS 12324-Expertise France). <i>Archives of Sexual Behavior</i> , 2020, 49, 331-345.	1.2	9
669	How Male Sex Workers and Their Clients Shifted from Reluctance About HIV Pre-exposure Prophylaxis to Advocating for Its Use: A Longitudinal Mixed Methods Study. <i>AIDS and Behavior</i> , 2020, 24, 782-790.	1.4	8
670	Identification and characterization of latent classes based on drug use among men who have sex with men at risk of sexually transmitted infections in Amsterdam, the Netherlands. <i>Addiction</i> , 2020, 115, 121-133.	1.7	27
672	Mieux comprendre les défis de la médicalisation de la prévention du VIH en France : la prophylaxie pré-exposition au prisme des sciences sociales. <i>Global Health Promotion</i> , 2020, 27, 149-153.	0.7	4
673	Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 574-582.	2.9	86
674	Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 249-255.	2.9	7
675	Social Support Networks Among Young Men and Transgender Women of Color Receiving HIV Pre-Exposure Prophylaxis. <i>Journal of Adolescent Health</i> , 2020, 66, 268-274.	1.2	10
676	Prevention of HIV Transmission and the HPTN 052 Study. <i>Annual Review of Medicine</i> , 2020, 71, 347-360.	5.0	25
677	Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial. <i>AIDS and Behavior</i> , 2020, 24, 1432-1442.	1.4	38
678	Responsibilization and Sexual Stigma Under Austerity: Surveying Public Support for Government-Funded PrEP in England. <i>Sexuality Research and Social Policy</i> , 2020, 17, 643-653.	1.4	2
679	The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 357-364.	0.9	40
680	Pre-exposure Prophylaxis Knowledge and Use Among Men Who Have Sex With Men in a Small Metropolitan Region of the Southeastern United States. <i>Journal of the Association of Nurses in AIDS Care</i> , 2020, 31, 80-91.	0.4	2
681	Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. <i>EclinicalMedicine</i> , 2020, 19, 100217.	3.2	13

#	ARTICLE	IF	CITATIONS
682	High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. <i>Journal of Hepatology</i> , 2020, 72, 855-864.	1.8	48
683	PrEP and Adolescents: The Role of Providers in Ending the AIDS Epidemic. <i>Pediatrics</i> , 2020, 145, .	1.0	27
684	Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and <i>Neisseria gonorrhoeae</i> transmission and cost-effectiveness. <i>Aids</i> , 2020, 34, 621-630.	1.0	11
685	Low Awareness of and Access to Pre-exposure Prophylaxis But High Interest Among Heterosexual Women in Cleveland, Ohio. <i>Sexually Transmitted Diseases</i> , 2020, 47, 96-99.	0.8	6
686	Active-Offer Nurse-Led PrEP (PrEP-RN) Referrals: Analysis of Uptake Rates and Reasons for Declining. <i>AIDS and Behavior</i> , 2020, 24, 1281-1289.	1.4	9
687	HIV treatment and prevention 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 4-12.	1.5	52
688	Facing increased sexually transmitted infection incidence in HIV preexposure prophylaxis cohorts: what are the underlying determinants and what can be done?. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 51-58.	1.3	9
689	Biomedical HIV Protection Among Gay and Bisexual Men Who Use Crystal Methamphetamine. <i>AIDS and Behavior</i> , 2020, 24, 1400-1413.	1.4	25
690	Informing theoretical development of salutogenic, asset-based health improvement to reduce syndemics among gay, bisexual and other men who have sex with men: Empirical evidence from secondary analysis of multi-national, online cross-sectional surveys. <i>SSM - Population Health</i> , 2020, 10, 100519.	1.3	10
691	On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. <i>Lancet HIV</i> , 2020, 7, e113-e120.	2.1	54
692	Eligibility for Pre-exposure Prophylaxis According to Different Guidelines in a Cohort of HIV-Negative Men Who Have Sex with Men in Lisbon, Portugal. <i>Sexuality Research and Social Policy</i> , 2020, 17, 688-699.	1.4	4
693	A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2020, 31, 85-87.	0.5	1
694	Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa455.	0.4	42
695	Exploring nurse-led HIV Pre-Exposure Prophylaxis in a community health care clinic. <i>Public Health Nursing</i> , 2020, 37, 871-879.	0.7	5
696	Knowledge, Attitudes, and Intentions towards HIV Pre-Exposure Prophylaxis among Nursing Students in Spain. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7151.	1.2	4
697	“Break the Chains 2015”™ community-based HIV prevention campaign for men who have sex with men in Switzerland: non-randomised evaluation and cost analysis. <i>BMJ Open</i> , 2020, 10, e032459.	0.8	1
698	“PrEP is like an adult using floaties”™: meanings and new identities of PrEP among a niche sample of gay men. <i>Culture, Health and Sexuality</i> , 2022, 24, 153-166.	1.0	10
699	Law Everywhere: A Causal Framework for Law and Infectious Disease. <i>Public Health Reports</i> , 2020, 135, 25S-31S.	1.3	5

#	ARTICLE	IF	CITATIONS
700	Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018. <i>Annals of Epidemiology</i> , 2020, 49, 1-7.	0.9	12
701	Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. <i>Drugs</i> , 2020, 80, 1881-1888.	4.9	5
702	Nondaily Use of HIV Preexposure Prophylaxis in a Large Online Survey of Primarily Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 182-188.	0.9	11
703	Ending the HIV Epidemic: New York's Quest to Become the First State to Reduce HIV Prevalence. <i>Public Health Reports</i> , 2020, 135, 65S-74S.	1.3	8
704	Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol. <i>BMJ Open</i> , 2020, 10, e040734.	0.8	18
705	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 239-254.	6.3	245
706	Trends in Human Immunodeficiency Virus and Sexually Transmitted Infection Testing Among Gay, Bisexual, and Other Men Who Have Sex With Men After Rapid Scale-up of Preexposure Prophylaxis in Victoria, Australia. <i>Sexually Transmitted Diseases</i> , 2020, 47, 516-524.	0.8	4
707	Recent declines in HIV infections at Silom Community Clinic Bangkok, Thailand corresponding to HIV prevention scale up: An open cohort assessment 2005-2018. <i>International Journal of Infectious Diseases</i> , 2020, 99, 131-137.	1.5	10
708	Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings. <i>Lancet HIV</i> , 2020, 7, e294-e300.	2.1	12
709	Profile of new HIV diagnoses and risk factors associated with late diagnosis in a specialized outpatient clinic during the 2014-2018 period. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 482-487.	0.1	3
710	Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men. <i>BMC Public Health</i> , 2020, 20, 1782.	1.2	33
711	Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China. <i>Chinese Medical Journal</i> , 2020, 133, 2840-2846.	0.9	8
712	Inflammation, HIV, and Immune Quiescence: Leveraging on Immunomodulatory Products to Reduce HIV Susceptibility. <i>AIDS Research and Treatment</i> , 2020, 2020, 1-16.	0.3	3
713	HIV stigma in UK press reporting of a case of intentional HIV transmission. <i>Health (United Kingdom)</i> , 2022, 26, 319-337.	0.9	7
714	Sexual desire and pleasure in the context of the HIV pre-exposure prophylaxis (PrEP). <i>Sexualities</i> , 2020, 23, 1400-1416.	0.8	13
715	Trial designs for evaluating combination HIV prevention approaches. <i>HIV Research and Clinical Practice</i> , 2020, 21, 72-82.	1.1	2
716	HIV Pre-Exposure Prophylaxis (PrEP) Counseling in Germany: Knowledge, Attitudes and Practice in Non-governmental and in Public HIV and STI Testing and Counseling Centers. <i>Frontiers in Public Health</i> , 2020, 8, 298.	1.3	5
717	Simulating the End of AIDS in New York: Using Participatory Dynamic Modeling to Improve Implementation of the Ending the Epidemic Initiative. <i>Public Health Reports</i> , 2020, 135, 158S-171S.	1.3	5

#	ARTICLE	IF	CITATIONS
718	Growth in Proportion and Disparities of HIV PrEP Use Among Key Populations Identified in the United States National Goals: Systematic Review and Meta-analysis of Published Surveys. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 379-386.	0.9	33
719	Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25495.	1.2	14
720	The Reemergence of Syphilis. <i>Nursing Clinics of North America</i> , 2020, 55, 361-377.	0.7	7
721	Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. <i>Scientific Reports</i> , 2020, 10, 12995.	1.6	3
722	Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol. <i>BMC Public Health</i> , 2020, 20, 1160.	1.2	8
723	Contraceptive use among sexually active women living with HIV in western Ethiopia. <i>PLoS ONE</i> , 2020, 15, e0237212.	1.1	4
724	To Pool or Not to Pool Samples for Sexually Transmitted Infections Detection in Men Who Have Sex With Men? An Evaluation of a New Pooling Method Using the GeneXpert Instrument in West Africa. <i>Sexually Transmitted Diseases</i> , 2020, 47, 556-561.	0.8	13
725	A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial. <i>Lancet HIV</i> , 2020, 7, e791-e796.	2.1	13
726	New strategies for prevention of HIV among Japanese men who have sex with men: a mathematical model. <i>Scientific Reports</i> , 2020, 10, 18187.	1.6	10
727	Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 454-457.	0.9	17
728	Meta-synthesis of Qualitative Research of Pre-exposure Prophylaxis (PrEP) Adherence Among Men Who Have Sex With Men (MSM). <i>AIDS Education and Prevention</i> , 2020, 32, 416-431.	0.6	13
729	Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin. <i>BMC Public Health</i> , 2020, 20, 1267.	1.2	18
730	Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. <i>Aids</i> , 2020, 34, 1699-1711.	1.0	21
731	Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa375.	0.4	33
732	Changes in mental health and drug use among men who have sex with men using daily and event-driven pre-exposure prophylaxis: Results from a prospective demonstration project in Amsterdam, the Netherlands. <i>EClinicalMedicine</i> , 2020, 26, 100505.	3.2	9
733	Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study. <i>Scientific Reports</i> , 2020, 10, 14609.	1.6	10
734	The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. <i>Aids</i> , 2020, 34, 883-891.	1.0	18
735	Factors Associated with Being PrEP-Naïve Among a U.S. National Cohort of Former-PrEP and PrEP-Naïve Participants Meeting Objective Criteria for PrEP Care. <i>Archives of Sexual Behavior</i> , 2021, 50, 1793-1803.	1.2	7

#	ARTICLE	IF	CITATIONS
736	Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. <i>Lancet Public Health</i> , The, 2020, 5, e501-e511.	4.7	20
737	Oral preexposure prophylaxis continuation, measurement and reporting. <i>Aids</i> , 2020, 34, 1801-1811.	1.0	31
738	Behavioral Counseling for Sexually Transmitted Infection Risk Reduction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 640.	3.8	1
739	Evaluating family physicians'™ willingness to prescribe PrEP. <i>MÃ©decine Et Maladies Infectieuses</i> , 2020, 50, 606-610.	5.1	4
740	Knowledge needs for implementing HIV pre-exposure prophylaxis among primary care providers in a safety-net health system. <i>Preventive Medicine Reports</i> , 2020, 20, 101266.	0.8	10
741	Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25636.	1.2	41
742	Exploring young Black gay, bisexual and other men who have sex with men's PrEP knowledge in Toronto, Ontario, Canada. <i>Culture, Health and Sexuality</i> , 2022, 24, 301-314.	1.0	9
743	Understanding the role of nurse practitioners, physician assistants and other nursing staff in HIV pre-exposure prophylaxis care in the United States: a systematic review and meta-analysis. <i>BMC Nursing</i> , 2020, 19, 117.	0.9	11
744	Hepatitis C infection among men who have sex with men living with HIV in New York City, 2000-2015. <i>Sexually Transmitted Infections</i> , 2020, 96, 445-450.	0.8	3
745	STI perspectives. <i>Sexually Transmitted Infections</i> , 2020, 96, 313-314.	0.8	0
746	Knowledge regarding post-exposure prophylaxis amongst nurses in an African context. <i>HIV and AIDS Review</i> , 2020, 19, 8-15.	0.1	3
747	Learning about how public involvement strengthens HIV research as a medical student. <i>Research Involvement and Engagement</i> , 2020, 6, 20.	1.1	2
748	Impact of PrEP on a STI clinic in a Belgian context: a provider's™ perspective. <i>Acta Clinica Belgica</i> , 2020, 76, 1-5.	0.5	0
749	Attitude of infectious diseases physicians in Turkey about HIV pre-exposure prophylaxis: results of an online survey. <i>International Journal of STD and AIDS</i> , 2020, 31, 665-670.	0.5	3
750	Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis. <i>Aids</i> , 2020, 34, 1181-1186.	1.0	16
751	Pre-exposure prophylaxis for HIV: A powerful preventive tool still underused. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 348-350.	0.1	0
752	Interest in Taking HIV Pre-exposure Prophylaxis Is Associated with Behavioral Risk Indicators and Self-Perceived HIV Risk Among Men Who Have Sex with Men Attending HIV Testing Venues in Sweden. <i>Archives of Sexual Behavior</i> , 2020, 49, 2165-2177.	1.2	8
753	Perspectives on HIV PrEP care in Germany: qualitative insights from primary care physicians and specialists. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 994-1000.	0.6	5

#	ARTICLE	IF	CITATIONS
754	Religion, faith, and spirituality influences on HIV prevention activities: A scoping review. PLoS ONE, 2020, 15, e0234720.	1.1	31
755	Are PrEP services in France reaching all those exposed to HIV who want to take PrEP? MSM respondents who are eligible but not using PrEP (EMIS 2017). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 47-56.	0.6	32
756	The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. Journal of the International AIDS Society, 2020, 23, e25463.	1.2	115
757	National trends in HIV pre-exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017. Journal of the International AIDS Society, 2020, 23, e25461.	1.2	105
760	Increase in the overall level of protected anal sex in men who have sex with men in France: results from the repeated cross-sectional survey Rapport au Sexe, France, 2017-2019. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 162-169.	0.6	9
761	Drug use, depression and sexual risk behaviour: a syndemic among early pre-exposure prophylaxis (PrEP) adopters in Belgium?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 57-64.	0.6	19
762	Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. BMC Public Health, 2020, 20, 271.	1.2	9
763	Exploring the Pre-exposure Prophylaxis (PrEP) Health Care Experiences Among Men Who Have Sex With Men (MSM) Who Live in Rural Areas of the Midwest. AIDS Education and Prevention, 2020, 32, 51-66.	0.6	28
764	Social network intervention to increase pre-exposure prophylaxis (PrEP) awareness, interest, and use among African American men who have sex with men. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 40-46.	0.6	36
765	Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility. AIDS Research and Human Retroviruses, 2020, 36, 721-733.	0.5	4
766	PrEP Interest Among Men Who Have Sex with Men in the Netherlands: Covariates and Differences Across Samples. Archives of Sexual Behavior, 2020, 49, 2155-2164.	1.2	10
767	A Survey on HIV/AIDS-Related Knowledge, Attitudes, Risk Behaviors, and Characteristics of Men Who Have Sex with Men among University Students in Guangxi, China. BioMed Research International, 2020, 1-10.	0.9	13
768	Pre-exposure prophylaxis among men who have sex with men in Côte d'Ivoire: a quantitative study of acceptability. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 1228-1236.	0.6	8
769	The Impact of Pre-exposure Prophylaxis for Human Immunodeficiency Virus on Gonorrhea Prevalence. Bulletin of Mathematical Biology, 2020, 82, 85.	0.9	4
770	Impact of Case Definitions on Efficacy Estimation in Clinical Trials—A Proof-of-Principle Based on Historical Examples. Antibiotics, 2020, 9, 379.	1.5	4
771	A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework. Journal of the International AIDS Society, 2020, 23, e25531.	1.2	12
772	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. Nature Communications, 2020, 11, 3195.	5.8	15
773	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV, the, 2020, 7, e472-e481.	2.1	97

#	ARTICLE	IF	CITATIONS
774	STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. <i>BMC Infectious Diseases</i> , 2020, 20, 110.	1.3	108
775	Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate + emtricitabine for HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25420.	1.2	13
776	Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. <i>Clinical Infectious Diseases</i> , 2020, 71, 3152-3153.	2.9	8
778	Understanding PrEP Persistence: Provider and Patient Perspectives. <i>AIDS and Behavior</i> , 2020, 24, 2509-2519.	1.4	48
779	Putting the NHS England on trial: uncertainty-as-power, evidence and the controversy of PrEP in England. <i>Medical Humanities</i> , 2020, 46, 176-179.	0.6	12
780	Using Motivational Interviewing to Increase PrEP Uptake Among Black Women at Risk for HIV: an Open Pilot Trial of MI-PrEP. <i>Journal of Racial and Ethnic Health Disparities</i> , 2020, 7, 913-927.	1.8	29
781	Sexually transmitted infection diagnoses, sexualised drug use and associations with pre-exposure prophylaxis use among men who have sex with men in the UK. <i>International Journal of STD and AIDS</i> , 2020, 31, 254-263.	0.5	1
782	Student Education About Pre-exposure Prophylaxis (PrEP) Varies Between Regions of the United States. <i>Journal of General Internal Medicine</i> , 2020, 35, 2873-2881.	1.3	15
783	Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review. <i>AIDS Patient Care and STDs</i> , 2020, 34, 111-123.	1.1	127
784	Human immunodeficiency virus prevention strategies in China. <i>Chinese Medical Journal</i> , 2020, 133, 318-325.	0.9	8
785	Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. <i>BMC Public Health</i> , 2020, 20, 69.	1.2	50
786	Antiretroviral treatment for HIV infection: Swedish recommendations 2019. <i>Infectious Diseases</i> , 2020, 52, 295-329.	1.4	13
787	The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. <i>AIDS and Behavior</i> , 2020, 24, 2178-2187.	1.4	13
788	Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. <i>PLoS Computational Biology</i> , 2020, 16, e1007482.	1.5	5
789	Assessing determinants of pre-exposure prophylaxis (PrEP) adherence among a sample of rural Midwestern men who have sex with men (MSM). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1581-1588.	0.6	13
790	Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial. <i>AIDS and Behavior</i> , 2020, 24, 3244-3251.	1.4	6
791	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
792	Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2020, 24, 3192-3204.	1.4	7

#	ARTICLE	IF	CITATIONS
793	Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. <i>AIDS and Behavior</i> , 2020, 24, 3056-3070.	1.4	50
794	Facilitators and Barriers of Pre-exposure Prophylaxis (PrEP) Uptake Among Rural Men who have Sex with Men Living in the Midwestern U.S.. <i>Archives of Sexual Behavior</i> , 2020, 49, 2179-2191.	1.2	38
795	Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 1778-1811.	1.3	187
797	PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options. <i>Cell Host and Microbe</i> , 2020, 27, 502-506.	5.1	30
798	Male partners' influence on women's acceptance and use of PrEP products across two high HIV-burdened districts in South Africa. <i>African Journal of AIDS Research</i> , 2020, 19, 93-100.	0.3	5
799	Introducing pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Sweden: insights from a mathematical pair formation model. <i>BMJ Open</i> , 2020, 10, e033852.	0.8	9
800	Knowledge and practices of Parisian family physicians for the management of men who have sex with men in the era of HIV pre-exposure prophylaxis. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 597-605.	5.1	3
801	Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. <i>Journal of the International AIDS Society</i> , 2020, 23, e25472.	1.2	40
802	Changes in Sexual Behaviors in Men Who Have Sex with Men: A Comparison Between the Double-Blind and Open-Label Extension Phases of the ANRS-IPERGAY Trial. <i>AIDS and Behavior</i> , 2020, 24, 3093-3106.	1.4	7
803	HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers. <i>AIDS and Behavior</i> , 2020, 24, 3124-3131.	1.4	11
804	High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 852-857.	1.0	10
805	"PROUD to have been involved": an evaluation of participant and community involvement in the PROUD HIV prevention trial. <i>Research Involvement and Engagement</i> , 2020, 6, 13.	1.1	5
806	Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. <i>PLoS ONE</i> , 2020, 15, e0231424.	1.1	26
807	Interest and Knowledge of HIV Pre-Exposure Prophylaxis in a Unified Jail and Prison Setting. <i>Journal of Correctional Health Care</i> , 2020, 26, 36-41.	0.2	11
808	Acceptability of electronic healthcare predictive analytics for HIV prevention: a qualitative study with men who have sex with men in New York City. <i>MHealth</i> , 2020, 6, 11-11.	0.9	4
809	Traditional Machismo, Caballerismo, and the Pre-Exposure Prophylaxis (PrEP) Cascade Among a Sample of Latino Sexual Minority Men. <i>Journal of Sex Research</i> , 2021, 58, 21-28.	1.6	15
810	"Now that PrEP is reducing the risk of transmission of HIV, why then do you still insist that we use condoms?" the condom quandary among PrEP users and health care providers in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 92-100.	0.6	12
811	Prevention of HIV transmission with sperm washing within fertile serodiscordant couples undergoing non-stimulated intrauterine insemination. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 478-485.	0.6	4

#	ARTICLE	IF	CITATIONS
812	Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 697-705.	0.6	45
813	Factors Associated with Preferred Pre-Exposure Prophylaxis Dosing Regimen Among Men Who Have Sex with Men in Real-World Settings: A Mixed-Effect Model Analysis. <i>AIDS and Behavior</i> , 2021, 25, 249-258.	1.4	9
814	A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections. <i>HIV Medicine</i> , 2021, 22, 75-82.	1.0	13
815	Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital. <i>Infectious Diseases Now</i> , 2021, 51, 357-361.	0.7	1
816	Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. <i>HIV Medicine</i> , 2021, 22, 67-72.	1.0	8
817	Community-Based Participatory Approaches to Knowledge Translation: HIV Prevention Case Study of the Investigaytors Program. <i>Archives of Sexual Behavior</i> , 2021, 50, 105-117.	1.2	5
818	Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants. <i>Chemical Biology and Drug Design</i> , 2021, 97, 4-17.	1.5	8
819	Examining the Potential of Pre-exposure Prophylaxis (PrEP) for HIV Prevention in a Community Sample of Persons Who Use Stimulants Living in the Southern United States. <i>AIDS and Behavior</i> , 2021, 25, 1480-1489.	1.4	2
820	Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men: real-life experience from three sexual health clinics in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e94-e96.	1.3	0
821	Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. <i>Journal of Investigative Medicine</i> , 2021, 69, 28-40.	0.7	4
822	DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2021, 25, 1001-1012.	1.4	29
823	Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention. <i>HIV Medicine</i> , 2021, 22, 185-193.	1.0	12
824	Addressing Unhealthy Alcohol Use and the HIV Pre-exposure Prophylaxis Care Continuum in Primary Care: A Scoping Review. <i>AIDS and Behavior</i> , 2021, 25, 1777-1789.	1.4	14
825	Blood Donation and COVID-19: Reconsidering the 3-Month Deferral Policy for Gay, Bisexual, Transgender, and Other Men Who Have Sex With Men. <i>American Journal of Public Health</i> , 2021, 111, 247-252.	1.5	15
826	Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study.. <i>International Journal of Drug Policy</i> , 2021, 88, 103033.	1.6	13
827	Pre-exposure Prophylaxis (PrEP) Awareness and Prescribing Behaviors Among Primary Care Providers: DocStyles Survey, 2016-2020, United States. <i>AIDS and Behavior</i> , 2021, 25, 1267-1275.	1.4	11
828	Reviewing PrEP's Effect on STI Incidence Among Men Who Have sex with Men: Balancing Increased STI Screening and Potential Behavioral Sexual Risk Compensation. <i>AIDS and Behavior</i> , 2021, 25, 1810-1818.	1.4	15
829	Socio-Sexual Experiences and Access to Healthcare Among Informal PrEP Users in the Netherlands. <i>AIDS and Behavior</i> , 2021, 25, 1236-1246.	1.4	9

#	ARTICLE	IF	CITATIONS
830	Development and Psychometric Evaluation of the PrEP Sexual Expectancies (PSEXS) Scale. <i>AIDS and Behavior</i> , 2021, 25, 1192-1198.	1.4	0
831	The PrEP response in England: enabling collective action through public health and PrEP commodity activism. <i>Critical Public Health</i> , 2021, 31, 226-234.	1.4	4
832	An evaluation of cabotegravir for HIV treatment and prevention. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 403-414.	0.9	6
833	The Impact of PrEP on the Sex Lives of MSM at High Risk for HIV Infection: Results of a Belgian Cohort. <i>AIDS and Behavior</i> , 2021, 25, 532-541.	1.4	4
834	Opioid use disorder and HIV. , 2021, , 51-75.		0
835	A rapid review of pre-exposure prophylaxis for HIV in the Asia-Pacific region: recommendations for scale up and future directions. <i>Sexual Health</i> , 2021, 18, 31.	0.4	10
836	Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. <i>Aids</i> , 2021, 35, 665-673.	1.0	38
837	Control and prevention of infectious diseases from a One Health perspective. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200256.	0.6	38
838	Behavior Change and Sexually Transmitted Incidence in Relation to PREP Use Among Men Who Have Sex with Men in Kenya. <i>AIDS and Behavior</i> , 2021, 25, 2219-2229.	1.4	6
840	Provision of Preexposure Prophylaxis at the Portuguese National Health Service and Uptake in the Lisbon Cohort of Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2021, 25, 1975-1983.	1.4	3
841	The Epidemiology of HIV Among Sex Workers Around the World: Implications for Research, Programmes, and Policy. , 2021, , 15-39.		2
842	Estimating the percentage of European MSM eligible for PrEP: insights from a bio-behavioural survey in thirteen cities. <i>Sexually Transmitted Infections</i> , 2021, 97, sextrans-2020-054786.	0.8	3
843	Barriers and facilitators to pre-exposure prophylaxis among African migrants in high income countries: a systematic review. <i>Sexual Health</i> , 2021, 18, 130-139.	0.4	12
844	Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women. <i>Seminars in Immunology</i> , 2021, 51, 101482.	2.7	9
845	United States Ending the Human Immunodeficiency Virus (HIV) Epidemic Plan: Evaluation of the Role of Industry Funding in Published Pre-Exposure Prophylaxis (PrEP) Literature. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
847	Anticipating Policy, Orienting Services, Celebrating Provision: Reflecting on Scotland's PrEP Journey. <i>Social Aspects of HIV</i> , 2021, , 59-72.	0.1	3
848	The Stigma Struggles of Biomedical Progress: Understanding Community Engagement with PrEP by People Who Use Drugs. <i>Social Aspects of HIV</i> , 2021, , 173-185.	0.1	0
849	â€œBelt and braces approach; added benefit andâ€œ extra reassuranceâ€œ a multi-stakeholder examination of the challenges to effective provision of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Northern and Central England. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 736-745.	0.6	2

#	ARTICLE	IF	CITATIONS
850	Implementation Science or "Show" Trial? England's PrEP Impact Study. <i>Social Aspects of HIV</i> , 2021, , 159-172.	0.1	2
851	Imagined Futures and Unintended Consequences in the Making of PrEP: An Evidence-Making Intervention Perspective. <i>Social Aspects of HIV</i> , 2021, , 249-264.	0.1	2
852	Pre-exposure prophylaxis makes it possible to better live one's sexuality and guide men who have sex with men towards a responsible approach to their health: a phenomenological qualitative study about primary motivations for PrEP. <i>AIDS Research and Therapy</i> , 2021, 18, 2.	0.7	5
853	HIV-Infektion " PrÄvalenz, Bedeutung und Implikationen f¼r die PrÄvention und GesundheitsfÄrderung. <i>The Springer Reference Pflögerapie, Gesundheit</i> , 2021, , 1001-1006.	0.2	0
854	Patient-Led Decision-Making for HIV Preexposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2021, 18, 48-56.	1.1	15
855	Predictors of Event-Driven Regimen Choice in Current PrEP Users and Sexual Behavior Characteristics of MSM Receiving Sexual Health Services in New York City. <i>AIDS and Behavior</i> , 2021, 25, 2410-2418.	1.4	7
856	Human Immunodeficiency Virus Preexposure Prophylaxis Knowledge, Attitudes and Perceptions of Sexual Health Risk in an Age of Sexually Transmitted Infection Antimicrobial Resistance. <i>Sexually Transmitted Diseases</i> , 2021, 48, 685-692.	0.8	5
857	Low use of condom and high STI incidence among men who have sex with men in PrEP programs. <i>PLoS ONE</i> , 2021, 16, e0245925.	1.1	15
858	Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. <i>Lancet HIV</i> ,the, 2021, 8, e77-e86.	2.1	55
859	Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25667.	1.2	20
860	Referral linkage to pre-exposure prophylaxis (PrEP) care and persistence on PrEP in an integrated healthcare system. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 918-927.	0.9	8
861	Clinical Presentation of Incident Syphilis Among Men Who Have Sex with Men Taking HIV Pre-Exposure Prophylaxis in Melbourne, Australia. <i>Clinical Infectious Diseases</i> , 2021, 73, e934-e937.	2.9	9
862	Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2021, 32, 806-815.	0.5	3
863	HIV Prevention Responsibility Beliefs Among Men Who Have Sex with Men in the PrEP Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, e222-e228.	0.9	2
864	Geographies of PrEP, TasP and undetectability: Reconceptualising HIV assemblages to explore what else matters in the lives of gay and bisexual men. <i>Dialogues in Human Geography</i> , 2022, 12, 100-118.	0.8	13
865	Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models. <i>PLoS ONE</i> , 2021, 16, e0246129.	1.1	16
866	Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. <i>International Journal of STD and AIDS</i> , 2021, 32, 638-647.	0.5	4
867	Real-Time Monitoring and Point-of-Care Testing: A Review of the Current Landscape of PrEP Adherence Monitoring. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 259-269.	0.8	14

#	ARTICLE	IF	CITATIONS
868	Missed opportunities for sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25673.	1.2	22
869	The Impact of Pre-exposure Prophylaxis on Sexual Well-Being Among Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2021, 50, 1829-1841.	1.2	9
870	High HIV prevalence, low awareness of and willingness to use HIV pre-exposure prophylaxis among male migrant workers in Southwestern, China: a short report. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 760-766.	0.6	2
871	Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 165-186.	1.8	13
872	Sexually Transmitted Infection Testing and Prevalence Before and After Preexposure Prophylaxis Initiation Among Men Aged ≥18 Years in US Private Settings. <i>Sexually Transmitted Diseases</i> , 2021, 48, 515-520.	0.8	3
873	From training wheels to chemical condoms: Exploring narratives of PrEP discontinuation. <i>Health (United Kingdom)</i> , 2021, , 136345932110051.	0.9	1
874	“The Main Concern is HIV, Everything Else is Fixable” Indifference Toward Sexually Transmitted Infections in the Era of Biomedical HIV Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2657-2660.	1.4	7
875	Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis. <i>Aids</i> , 2021, 35, 1113-1125.	1.0	10
876	A Randomized Trial of a Brief Behavioral Intervention for PrEP Uptake Among Men Who Have Sex With Men at Increased Risk for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 937-943.	0.9	11
877	Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab085.	0.4	0
878	Antiretroviral therapy based HIV prevention targeting young women who sell sex: a mixed method approach to understand the implementation of PrEP in a rural area of KwaZulu-Natal, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 232-240.	0.6	11
879	Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study. <i>Scientific Reports</i> , 2021, 11, 6798.	1.6	5
880	Development and Evaluation of a Mobile App Designed to Increase HIV Testing and Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men in the United States: Open Pilot Trial. <i>Journal of Medical Internet Research</i> , 2021, 23, e25107.	2.1	29
881	Harm Reduction in Sexual Medicine. <i>Sexual Medicine Reviews</i> , 2022, 10, 3-22.	1.5	21
882	Primary HIV-1 infection in users of pre-exposure prophylaxis. <i>Lancet HIV</i> , 2021, 8, e166-e174.	2.1	23
883	Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 141-152.	0.8	0
884	Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 674-681.	2.4	6
885	Infection with antiretroviral-susceptible HIV in an individual adherent to pre-exposure prophylaxis: strategies for treatment initiation. <i>International Journal of STD and AIDS</i> , 2021, 32, 578-581.	0.5	1

#	ARTICLE	IF	CITATIONS
886	Pre-exposure prophylaxis (PrEP) and "risk"™ in the news. <i>Journal of Risk Research</i> , 2022, 25, 379-394.	1.4	4
887	The AMP Trials " A Glass Half Full. <i>New England Journal of Medicine</i> , 2021, 384, 1068-1069.	13.9	7
888	Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. <i>Sexually Transmitted Infections</i> , 2022, 98, 132-135.	0.8	10
889	Implementing Implementation Research: Teaching Implementation Research to HIV Researchers. <i>Current HIV/AIDS Reports</i> , 2021, 18, 186-197.	1.1	4
890	Preexposure prophylaxis care continuum among transgender women at a patient-centered preexposure prophylaxis program in Atlanta, Georgia. <i>Aids</i> , 2021, 35, 524-526.	1.0	3
891	Geographic Density and Uptake of Pre-exposure Prophylaxis (PrEP) Among Young Gay, Bisexual and Other Sexual Minority Men: A Global Positioning System (GPS) Study. <i>AIDS and Behavior</i> , 2021, 25, 155-164.	1.4	6
892	Knowledge, Attitudes and Practices Regarding Pre-Exposure Prophylaxis (PrEP) in a Sample of Italian Men Who Have SEX with MEN (MSM). <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4772.	1.2	8
893	The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. <i>Journal of Viral Hepatitis</i> , 2021, 28, 897-908.	1.0	3
894	Sexual Dysfunction in Men Who Have Sex With Men. <i>Sexual Medicine Reviews</i> , 2022, 10, 130-141.	1.5	13
895	Use of HIV pre-exposure prophylaxis among urban Canadian gay, bisexual and other men who have sex with men: a cross-sectional analysis of the Engage cohort study. <i>CMAJ Open</i> , 2021, 9, E529-E538.	1.1	41
896	Access to Subsidized Health Care Affects HIV Pre-Exposure Prophylaxis (PrEP) Uptake Among Gay and Bisexual Men in Australia: Results of National Surveys 2013-2019. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 430-435.	0.9	22
897	Offering a choice of daily and event-driven preexposure prophylaxis for men who have sex with men in the Netherlands: a cost-effectiveness analysis. <i>Aids</i> , 2021, 35, 1677-1682.	1.0	2
898	Developing and testing of an interactive internet-based intervention to reduce sexual harm of sexualised drug use ("chemsex"™) among men who have sex with men in Hong Kong: a study protocol for a randomised controlled trial. <i>BMC Public Health</i> , 2021, 21, 713.	1.2	6
899	Primary Care Providers'™ Perspectives on Using Automated HIV Risk Prediction Models to Identify Potential Candidates for Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2021, 25, 3651-3657.	1.4	8
900	HIV Pre-exposure Prophylaxis (PrEP): Knowledge, attitudes and counseling practices among physicians in Germany " A cross-sectional survey. <i>PLoS ONE</i> , 2021, 16, e0250895.	1.1	1
901	Structural Issues Associated with Pre-exposure Prophylaxis Use in Men Who Have Sex with Men. <i>International Journal of Behavioral Medicine</i> , 2021, 28, 759-767.	0.8	7
902	Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1245-1251.	0.9	2
903	Evaluation of Drug Abuse by Hair Analysis and Self-Reported Use Among MSM Under PrEP; Results From a French Substudy of the ANRS-IPERGAY Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 552-561.	0.9	9

#	ARTICLE	IF	CITATIONS
904	Differences in PrEP Awareness, Discussions with Healthcare Providers, and Use Among Men Who Have Sex with Men in the United States by Urbanicity and Region: A Cross-sectional Analysis. <i>AIDS and Behavior</i> , 2021, 25, 4102-4114.	1.4	14
905	Imperfect adherence in real life: a prevention-effective perspective on adherence to daily and event-driven HIV pre-exposure prophylaxis among men who have sex with men – a prospective cohort study in Taiwan. <i>Journal of the International AIDS Society</i> , 2021, 24, e25733.	1.2	18
906	Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application. <i>Aids</i> , 2021, 35, 1823-1834.	1.0	7
907	Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project. <i>International Journal of STD and AIDS</i> , 2021, 32, 1060-1065.	0.5	3
908	A qualitative assessment in acceptability and barriers to use pre-exposure prophylaxis (PrEP) among men who have sex with men: implications for service delivery in Vietnam. <i>BMC Infectious Diseases</i> , 2021, 21, 472.	1.3	11
909	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. <i>Aids</i> , 2021, 35, 1567-1574.	1.0	6
910	Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25744.	1.2	12
911	Recurrent Sexually Transmitted Infections Among a Cohort of Men Who Have Sex With Men Using Preexposure Prophylaxis in Belgium Are Highly Associated With Sexualized Drug Use. <i>Sexually Transmitted Diseases</i> , 2021, 48, 726-732.	0.8	5
912	A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 680-687.	0.9	25
913	Tempering hope with Intimate Knowledge: Contrasting emergences of the concept “uninfectious”™ in HIV. <i>Sociology of Health and Illness</i> , 2021, 43, 1100-1116.	1.1	2
914	Incidence of Sexually Transmitted Infections After Initiating HIV Pre-Exposure Prophylaxis Among MSM in Southern Denmark. <i>American Journal of Men's Health</i> , 2021, 15, 155798832110189.	0.7	7
915	Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. <i>BMC Public Health</i> , 2021, 21, 943.	1.2	4
916	HIV Pre-Exposure Prophylaxis, Condoms, or Both? Insights on Risk Compensation Through a Discrete Choice Experiment and Latent Class Analysis Among Men Who Have Sex With Men. <i>Value in Health</i> , 2021, 24, 714-723.	0.1	8
917	Platforms for Personalized Polytherapeutics Discovery in COVID-19. <i>Journal of Molecular Biology</i> , 2021, 433, 166945.	2.0	4
918	Scaling Up and Out HIV Prevention and Behavioral Health Services to Latino Sexual Minority Men in South Florida: Multi-Level Implementation Barriers, Facilitators, and Strategies. <i>AIDS Patient Care and STDs</i> , 2021, 35, 167-179.	1.1	24
919	Social and Behavioral Correlates of Sexually Transmitted Infections among Men who Have Sex with Men who Use Alcohol in the San Francisco Bay Area. <i>American Journal of Men's Health</i> , 2021, 15, 155798832110268.	0.7	4
920	Inflammatory cytologic alterations in the oral epithelium associated with HIV pre-exposure prophylaxis: a preliminary study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 534-539.	0.2	2
921	Experiencia de un programa de profilaxis preexposici3n en una unidad de virus de la inmunodeficiencia humana hospitalaria. Descripci3n del perfil basal del usuario e identificaci3n de oportunidades de mejora. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2023, 41, 24-28.	0.3	7

#	ARTICLE	IF	CITATIONS
922	Characteristics of newly diagnosed HIV-positive service users using a pan-London e-sexually transmitted infection screening service. <i>International Journal of STD and AIDS</i> , 2021, 32, 1036-1042.	0.5	2
923	The social meanings of PrEP use – A mixed-method study of PrEP use disclosure in Antwerp and Amsterdam. <i>Sociology of Health and Illness</i> , 2021, 43, 1311-1327.	1.1	7
924	The Value of Assessing Self-Reported and Biological Indicators of Outcomes in Evaluating HIV Programs. <i>Current HIV/AIDS Reports</i> , 2021, 18, 365-376.	1.1	1
926	Predictors of HIV Status Disclosure to Sexual Partners Among People Living with HIV in Brazil. <i>AIDS and Behavior</i> , 2021, 25, 3538-3546.	1.4	2
927	HIV Pre-exposure Prophylaxis in the LGBTQ Community: A Review of Practice and Places. <i>Cureus</i> , 2021, 13, e15518.	0.2	4
928	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <i>Current HIV/AIDS Reports</i> , 2021, 18, 261-270.	1.1	5
929	Understanding advances in treatment and care of people living with and alongside HIV: Contributions from the Sociology of Health and Illness. <i>Sociology of Health and Illness</i> , 2021, 43, 1079-1084.	1.1	0
930	Population-Level Effectiveness of HIV Pre-exposure Prophylaxis Among MSM and Transgender Persons With Bacterial Sexually Transmitted Infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 769-775.	0.9	10
931	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. <i>Aids</i> , 2021, 35, 2129-2136.	1.0	6
932	Minimum dataset for monitoring national human immunodeficiency virus pre-exposure prophylaxis (HIV PrEP) programmes: a five-nation consensus, 2019. <i>Eurosurveillance</i> , 2021, 26, .	3.9	3
933	Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide. <i>Journal for Nurse Practitioners</i> , 2021, 17, 673-676.	0.4	1
934	Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada?. <i>Epidemics</i> , 2021, 35, 100461.	1.5	3
935	Reflections on 40 Years of AIDS. <i>Emerging Infectious Diseases</i> , 2021, 27, 1553-1560.	2.0	49
936	Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland. <i>Value in Health</i> , 2021, 24, 948-956.	0.1	3
937	Effect of peer-distributed HIV self-test kits on demand for biomedical HIV prevention in rural KwaZulu-Natal, South Africa: a three-armed cluster-randomised trial comparing social networks versus direct delivery. <i>BMJ Global Health</i> , 2021, 6, e004574.	2.0	23
938	Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study. <i>Lancet HIV</i> , 2021, 8, e440-e448.	2.1	11
939	Factors associated with self-reported adherence to daily oral pre-exposure prophylaxis among men who have sex with man and transgender women: PrEP Brasil study. <i>International Journal of STD and AIDS</i> , 2021, 32, 1231-1241.	0.5	5
941	Delivering PrEP to Young Women in a Low-Income Setting in South Africa: Lessons for Providing Both Convenience and Support. <i>AIDS and Behavior</i> , 2022, 26, 147-159.	1.4	9

#	ARTICLE	IF	CITATIONS
942	The success of HIV combination prevention: The Dean Street model. <i>HIV Medicine</i> , 2021, 22, 892-897.	1.0	8
943	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2675-2680.	1.3	6
944	Renal impairment in a large-scale HIV pre-exposure prophylaxis implementation cohort. <i>Aids</i> , 2021, Publish Ahead of Print, 2319-2326.	1.0	5
945	Sexually Transmitted Infections Treatment Guidelines, 2021. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-187.	26.7	841
946	A cross-sectional survey of general practitioner knowledge, attitudes, and clinical experience of HIV PrEP. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 0, , 1.	0.8	0
947	Can HIV epidemics among MSM be eliminated through participation in preexposure prophylaxis rollouts?. <i>Aids</i> , 2021, 35, 2347-2354.	1.0	3
948	Internet-Based HIV Self-Testing Among Men Who Have Sex With Men Through Pre-exposure Prophylaxis: 3-Month Prospective Cohort Analysis From China. <i>Journal of Medical Internet Research</i> , 2021, 23, e23978.	2.1	8
949	High Levels of Prevention-Effective Adherence to HIV PrEP: An Analysis of Substudy Data From the EPIC-NSW Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1040-1047.	0.9	15
950	Evidence of changing sexual behaviours and clinical attendance patterns, alongside increasing diagnoses of STIs in MSM and TPSM. <i>Sexually Transmitted Infections</i> , 2021, 97, 507-513.	0.8	10
951	Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. <i>Lancet HIV</i> , 2021, 8, e486-e494.	2.1	54
952	Choosing event-driven and daily HIV pre-exposure prophylaxis – data from two European PrEP demonstration projects among men who have sex with men. <i>Journal of the International AIDS Society</i> , 2021, 24, e25768.	1.2	13
953	Discussion and Initiation of HIV Pre-exposure Prophylaxis Were Rare Following Diagnoses of Sexually Transmitted Infections Among Veterans. <i>Journal of General Internal Medicine</i> , 2021, , 1.	1.3	0
954	Are men who have sex with men at higher risk for HIV in Latin America more aware of PrEP?. <i>PLoS ONE</i> , 2021, 16, e0255557.	1.1	7
955	Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120844.	2.6	17
956	Brief Report: Low Incidence of Hepatitis C Among a Cohort of HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP) in Melbourne, Australia, and the Contribution of Sexual Transmission. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1011-1015.	0.9	4
957	Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe. <i>Frontiers in Medicine</i> , 2021, 8, 722247.	1.2	2
958	Managing risk, managing affects: The emerging biopolitics of HIV neutrality. <i>Health, Risk and Society</i> , 0, , 1-21.	0.9	2
959	A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. <i>Frontiers in Immunology</i> , 2021, 12, 726419.	2.2	28

#	ARTICLE	IF	CITATIONS
960	The Effect of PrEP Use Disclosure on Adherence in a Cohort of Adolescent Girls and Young Women in South Africa. <i>AIDS and Behavior</i> , 2022, 26, 1007-1016.	1.4	7
961	A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026). <i>AIDS Research and Human Retroviruses</i> , 2021, , .	0.5	5
962	An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 279-287.	0.5	7
964	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. <i>Vaccines</i> , 2021, 9, 1001.	2.1	2
966	Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs. <i>HIV Medicine</i> , 2021, 22, 965-970.	1.0	11
967	Underlying factors related to HIV/AIDS prevention: investigating the willingness to take pre-exposure prophylaxis among men-who-have-sex-with-men in Germany. <i>AIDS Research and Therapy</i> , 2021, 18, 61.	0.7	2
968	Can We Predict Incorrect PrEP Use in High HIV Risk Situations Among Men Who Have Sex With Men? An Analysis of Be-PrEP-ared, the Belgian PrEP Demonstration Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 36-44.	0.9	1
969	Merging care and prevention: preventive properties of antiretroviral drugs and HIV chronification in the case of Switzerland. <i>Anthropology and Medicine</i> , 2021, , 1-15.	0.6	0
970	What Will It Take to End HIV in the United States?. <i>Annals of Internal Medicine</i> , 2021, 174, 1542-1553.	2.0	12
971	The spatiotemporal distribution of pre-exposure prophylaxis accessibility in the United States, 2016-2020. <i>Annals of Epidemiology</i> , 2021, 64, 102-110.	0.9	10
972	Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex With Men in Ottawa: A Real World View With Benefits Beyond HIV Risk Reduction. <i>International Journal of Sexual Health</i> , 0, , 1-13.	1.2	0
973	Reddit on PrEP: Posts About Pre-exposure Prophylaxis for HIV from Reddit Users, 2014-2019. <i>AIDS and Behavior</i> , 2022, 26, 1084-1094.	1.4	6
974	Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro. <i>Molecular Pharmacology</i> , 2021, 100, 588-596.	1.0	5
975	Trends in undiagnosed HIV prevalence in England and implications for eliminating HIV transmission by 2030: an evidence synthesis model. <i>Lancet Public Health</i> , The, 2021, 6, e739-e751.	4.7	10
976	Awareness of and willingness to use HIV pre-exposure prophylaxis among community residents. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1957-1961.	1.5	2
977	Drug resistance mutations in HIV: new bioinformatics approaches and challenges. <i>Current Opinion in Virology</i> , 2021, 51, 56-64.	2.6	23
978	PrEP Is a Programme™: What Does this Mean for Policy. <i>Social Aspects of HIV</i> , 2021, , 21-34.	0.1	1
979	The Political Life of PrEP in England: An Ethnographic Account. <i>Social Aspects of HIV</i> , 2021, , 145-158.	0.1	2

#	ARTICLE	IF	CITATIONS
980	A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use. <i>AIDS Patient Care and STDs</i> , 2021, 35, 23-30.	1.1	26
981	Acquired immune deficiency syndrome (AIDS) and late presentation in Poland – data from Test and Keep in Care (TAK) Polska project. <i>HIV Medicine</i> , 2021, 22, 387-396.	1.0	12
982	Acesso a PrEP por homens cisgênero e transexuais: Um estudo de abordagem qualitativa. <i>Research, Society and Development</i> , 2021, 10, e44310111843.	0.0	0
983	A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa. <i>BMC Health Services Research</i> , 2021, 21, 17.	0.9	13
984	Cost-effectiveness of two screening strategies for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> as part of the PrEP programme in the Netherlands: a modelling study. <i>Sexually Transmitted Infections</i> , 2021, 97, 607-612.	0.8	15
985	Implementation of a national HIV pre-exposure prophylaxis service is associated with changes in characteristics of people with newly diagnosed HIV: a retrospective cohort study. <i>Sexually Transmitted Infections</i> , 2022, 98, 53-57.	0.8	6
986	The Democratic Biopolitics of PrEP. <i>Politologische Aufklärung - Konstruktivistische Perspektiven</i> , 2019, , 121-153.	0.4	14
988	Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. <i>Prevention Science</i> , 2017, 18, 737-747.	1.5	104
989	Role of Social and Sexual Network Factors in PrEP Utilization Among YMSM and Transgender Women in Chicago. <i>Prevention Science</i> , 2019, 20, 1089-1097.	1.5	31
990	Perfil de los nuevos diagnósticos de infección por VIH y factores de riesgo asociados al diagnóstico tardío en una consulta especializada durante el periodo 2014-2018. <i>Medicina Clínica</i> , 2020, 155, 482-487.	0.3	4
991	La implementación de la profilaxis preexposición podrá evitar la mayoría de las nuevas infecciones por el VIH en hombres que tienen sexo con hombres y mujeres transexuales. <i>Revista Clínica Española</i> , 2019, 219, 360-366.	0.2	8
992	Access to sexual health services after the rapid roll out of the launch of pre-exposure prophylaxis for HIV in Melbourne, Australia: a retrospective cross-sectional analysis. <i>Sexual Health</i> , 2018, 15, 528.	0.4	14
993	Baseline characteristics of gay and bisexual men in a HIV pre-exposure prophylaxis demonstration project with equity quotas in Auckland, New Zealand. <i>Sexual Health</i> , 2019, 16, 47.	0.4	7
994	Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017. <i>Sexual Health</i> , 2019, 16, 56.	0.4	7
995	Social and behavioural research prospects for sexually transmissible infection prevention in the era of advances in biomedical approaches. <i>Sexual Health</i> , 2020, 17, 103.	0.4	4
996	PrEP in the press. <i>Journal of Language and Sexuality</i> , 2020, 9, 202-225.	0.5	13
997	Differing Experiences with Pre-Exposure Prophylaxis in Boston Among Lesbian, Gay, Bisexual, and Transgender Specialists and Generalists in Primary Care: Implications for Scale-Up. <i>AIDS Patient Care and STDs</i> , 2017, 31, 297-304.	1.1	39
998	Health Profession Students' Awareness, Knowledge, and Confidence Regarding Preexposure Prophylaxis: Results of a National, Multidisciplinary Survey. <i>Sexually Transmitted Diseases</i> , 2021, 48, 25-31.	0.8	9

#	ARTICLE	IF	CITATIONS
999	Decision-making regarding condom use among daily and event-driven users of preexposure prophylaxis in the Netherlands. <i>Aids</i> , 2020, 34, 2295-2304.	1.0	16
1001	Patterns of sexualised recreational drug use and its association with risk behaviours and sexual health outcomes in men who have sex with men in London, UK: a comparison of cross-sectional studies conducted in 2013 and 2016. <i>Sexually Transmitted Infections</i> , 2020, 96, 197-203.	0.8	19
1002	Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation. <i>American Journal of Men's Health</i> , 2019, 13, 155798831982739.	0.7	54
1003	Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. <i>Gates Open Research</i> , 0, 3, 1504.	2.0	15
1004	Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. <i>Gates Open Research</i> , 2019, 3, 1504.	2.0	17
1005	HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project. <i>PLoS Medicine</i> , 2017, 14, e1002444.	3.9	124
1006	Who Will Use Pre-Exposure Prophylaxis (PrEP) and Why?: Understanding PrEP Awareness and Acceptability amongst Men Who Have Sex with Men in the UK – A Mixed Methods Study. <i>PLoS ONE</i> , 2016, 11, e0151385.	1.1	47
1007	Prioritizing Risk in Preparation for a Demonstration Project: A Mixed Methods Feasibility Study of Oral Pre-Exposure Prophylaxis (PREP) among Female Sex Workers in South India. <i>PLoS ONE</i> , 2016, 11, e0166889.	1.1	28
1008	Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men. <i>PLoS ONE</i> , 2017, 12, e0169484.	1.1	35
1009	Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. <i>PLoS ONE</i> , 2017, 12, e0173057.	1.1	24
1010	HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. <i>PLoS ONE</i> , 2017, 12, e0178594.	1.1	4
1011	Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. <i>PLoS ONE</i> , 2017, 12, e0181702.	1.1	9
1012	A novel polyepitope vaccine elicited HIV peptide specific CD4+ T cell responses in HLA-A2/DRB1 transgenic mice. <i>PLoS ONE</i> , 2017, 12, e0184207.	1.1	6
1013	Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project. <i>PLoS ONE</i> , 2017, 12, e0185398.	1.1	7
1014	HIV transmission and pre-exposure prophylaxis in a high risk MSM population: A simulation study of location-based selection of sexual partners. <i>PLoS ONE</i> , 2017, 12, e0189002.	1.1	4
1015	Sexual behavior experiences and characteristics of male-female partnerships among HIV positive adolescent girls and young women: Qualitative findings from Zimbabwe. <i>PLoS ONE</i> , 2018, 13, e0194732.	1.1	23
1016	Setting the stage for expanding HIV pre-exposure prophylaxis use in Canada. <i>Canada Communicable Disease Report</i> , 2017, 43, 272-278.	0.6	17
1017	A Guide for Designing Student-Led, Interprofessional Community Education Initiatives About HIV Risk and Pre-Exposure Prophylaxis. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 2019, 15, 10818.	0.5	17

#	ARTICLE	IF	CITATIONS
1018	Cost-Effectiveness of Interventions to Prevent HIV Acquisition. , 2017, , 137-155.		8
1019	Pre-Exposure Prophylaxis (PrEP) in Men Who have Sex with Men in Bouaké, Côte d'Ivoire: A Qualitative Evaluation of Acceptability. Open AIDS Journal, 2019, 13, 49-58.	0.1	7
1020	A Pre-Exposure Prophylaxis Adherence Intervention (LifeSteps) for Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e10661.	0.5	13
1021	A Mobile-Based App (MyChoices) to Increase Uptake of HIV Testing and Pre-Exposure Prophylaxis by Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e10694.	0.5	59
1022	Quality of HIV Websites With Information About Pre-Exposure Prophylaxis or Treatment as Prevention for Men Who Have Sex With Men: Systematic Evaluation. JMIR Public Health and Surveillance, 2018, 4, e11384.	1.2	5
1023	The PrEP You Want: A Web-Based Survey of Online Cross-Border Shopping for HIV Prophylaxis Medications. Journal of Medical Internet Research, 2019, 21, e12076.	2.1	2
1024	A Crowdsourced Physician Finder Prototype Platform for Men Who Have Sex with Men in China: Qualitative Study of Acceptability and Feasibility. JMIR Public Health and Surveillance, 2019, 5, e13027.	1.2	14
1025	Factors Associated With Willingness to Use Pre-Exposure Prophylaxis in Brazil, Mexico, and Peru: Web-Based Survey Among Men Who Have Sex With Men. JMIR Public Health and Surveillance, 2019, 5, e13771.	1.2	58
1026	An Electronic Pre-Exposure Prophylaxis Initiation and Maintenance Home Care System for Nonurban Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e13982.	0.5	41
1027	Mobile App (UPrEPU) to Monitor Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men: Protocol for a User-Centered Approach to Mobile App Design and Development. JMIR Research Protocols, 2020, 9, e20360.	0.5	9
1028	A Simple Pre-Exposure Prophylaxis (PrEP) Optimization Intervention for Health Care Providers Prescribing PrEP: Pilot Study. JMIR Formative Research, 2018, 2, e2.	0.7	19
1029	Usability and Acceptability of a Mobile Comprehensive HIV Prevention App for Men Who Have Sex With Men: A Pilot Study. JMIR MHealth and UHealth, 2017, 5, e26.	1.8	129
1030	Developing a Web-Based Geolocated Directory of HIV Pre-Exposure Prophylaxis-Providing Clinics: The PrEP Locator Protocol and Operating Procedures. JMIR Public Health and Surveillance, 2017, 3, e58.	1.2	48
1031	Awareness of Prevention Strategies and Willingness to Use Preexposure Prophylaxis in Brazilian Men Who Have Sex With Men Using Apps for Sexual Encounters: Online Cross-Sectional Study. JMIR Public Health and Surveillance, 2018, 4, e11.	1.2	43
1032	Development of an Agent-Based Model to Investigate the Impact of HIV Self-Testing Programs on Men Who Have Sex With Men in Atlanta and Seattle. JMIR Public Health and Surveillance, 2018, 4, e58.	1.2	14
1033	Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study). JMIR Research Protocols, 2016, 5, e128.	0.5	7
1034	Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol. JMIR Research Protocols, 2017, 6, e11.	0.5	27
1035	Rilpivirine: The Key for Long-term Success. AIDS Reviews, 2017, 19, .	0.5	7

#	ARTICLE	IF	CITATIONS
1037	Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). <i>Eurosurveillance</i> , 2017, 22, .	3.9	26
1038	Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe. <i>Eurosurveillance</i> , 2017, 22, .	3.9	13
1039	Combination prevention and HIV: a cross-sectional community survey of gay and bisexual men in London, October to December 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	14
1040	New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	3.9	4
1041	Estimating the "PrEP Gap": how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. <i>Eurosurveillance</i> , 2019, 24, .	3.9	57
1042	Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. <i>Eurosurveillance</i> , 2019, 24, .	3.9	21
1043	Travelling for sex, attending gay-specific venues, and HIV-related sexual risk among men who have sex with men in Ontario, Canada. <i>Canadian Journal of Human Sexuality</i> , 2020, 29, 380-391.	0.6	4
1044	Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India. <i>Indian Journal of Medical Research</i> , 2016, 143, 125.	0.4	7
1046	Consommation de substances en contexte sexuel chez des hommes gbHSH de Montr�al: 2009-2016. <i>Drogues, Sant� Et Soci�t�</i> , 0, 17, 76-94.	0.1	4
1048	Transitions Between Preexposure Prophylaxis Eligibility States and HIV Infection in The Lisbon Cohort of HIV-Negative Men Who Have Sex with Men: a Multistate Model Analysis. <i>American Journal of Epidemiology</i> , 2021, , .	1.6	1
1049	Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection. <i>HIV Medicine</i> , 2022, 23, 146-158.	1.0	8
1050	PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure. <i>AIDS and Behavior</i> , 2022, 26, 1308-1320.	1.4	20
1051	Development of a Mobile Health Application for HIV Prevention Among At-Risk Populations in Urban Settings in East Africa: A Participatory Design Approach. <i>JMIR Formative Research</i> , 2021, 5, e23204.	0.7	13
1052	The relevance of pre-exposure prophylaxis in gay men's lives and their motivations to use it: a qualitative study. <i>BMC Public Health</i> , 2021, 21, 1829.	1.2	8
1053	Provider Comfort with Prescribing HIV Pre-Exposure Prophylaxis to Adolescents. <i>AIDS Patient Care and STDs</i> , 2021, 35, 411-417.	1.1	22
1054	Experiences and challenges in sexual health service access among men who have sex with men in Kenya. <i>Global Public Health</i> , 2022, 17, 1626-1637.	1.0	5
1055	Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. <i>AIDS Patient Care and STDs</i> , 2021, 35, 419-427.	1.1	6
1056	Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab492.	0.4	1

#	ARTICLE	IF	CITATIONS
1057	Pre-Exposure Prophylaxis (PrEP) Adherence Questionnaire: Psychometric Validation among Sexually Transmitted Infection Patients in China. International Journal of Environmental Research and Public Health, 2021, 18, 10980.	1.2	2
1058	Limited risk compensation among women who inject drugs. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, .	0.8	0
1059	Pre-exposure prophylaxis failure with a multiple drug-resistant HIV-1 clade C virus in Brazil. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	0.9	0
1060	Academic Detailing to Increase Prescribing of HIV Pre-exposure Prophylaxis. American Journal of Preventive Medicine, 2021, 61, S87-S97.	1.6	4
1061	HIV prevention & treatment - Reasons to rejoice & remain vigilant. Indian Journal of Medical Research, 2015, 142, 633.	0.4	1
1062	Sex, piller og moral. , 2016, 32, 285-295.	0.1	0
1063	Sexually Transmitted Infections in Men Who Have Sex with Men. , 2017, , 193-219.		0
1065	Community acceptance and HIV sexual risk among gay and bisexual men in a "atypical" Canadian city. Canadian Journal of Human Sexuality, 2017, 26, 7-16.	0.6	4
1067	INTRODUCING TRAINING RELATED TO THE USE OF DRUGS TO PROTECT HUMANS FROM HIV INFECTION. , 2017, , .		3
1069	Not PrEPared to wait any longer: advocating for the use of PrEP in a HIV prevention strategy. Journal of Global Health Reports, 0, 1, .	1.0	0
1070	Knowledge, Normative Beliefs and Attitudes Related to Recent HIV Infection among People who Inject Drugs in Athens, Greece. Current HIV Research, 2018, 15, 386-395.	0.2	0
1076	Disease Presentation, Recognition and Prevention. , 2019, , 3-63.		0
1077	Knowledge, Attitude and Practice of Healthcare Workers Towards Availability of Antiretroviral Pre-Exposure Prophylaxis in Nigeria. Journal of Clinical Research in HIV AIDS and Prevention, 2018, 3, 46-59.	0.1	3
1078	HIV-Infektion " Pravalenz, Bedeutung und Implikationen fur die Prvention und Gesundheitsforderung. The Springer Reference Pfliegerapie, Gesundheit, 2019, , 1-6.	0.2	0
1079	Enumerating the population eligible for funded HIV pre-exposure prophylaxis (PrEP) in New Zealand. Sexual Health, 2019, 16, 63.	0.4	4
1080	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2019, , 1-22.		0
1081	Perceptions of people who inject drugs towards HIV pre-exposure prophylaxis in Australia. Sexual Health, 2019, 16, 383.	0.4	0
1084	Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention. International Journal of Biology, 2019, 11, 80.	0.1	4

#	ARTICLE	IF	CITATIONS
1085	¿Para cuándo la implantación de la profilaxis pre-exposición frente al VIH en España? Revista Clínica Española, 2019, 219, 396-397.	0.2	0
1088	La profilaxis pre-exposición en el VIH: una potente herramienta preventiva todavía infrutilizada. Medicina Clínica, 2020, 154, 348-350.	0.3	0
1089	Network Analysis of Organizations Providing HIV Services in Chicago. Journal of Public Health Management and Practice, 2020, Publish Ahead of Print, .	0.7	1
1091	Quantifying heterogeneity in sexual behaviour and distribution of STIs before and after pre-exposure prophylaxis among men who have sex with men. Sexually Transmitted Infections, 2022, 98, 395-400.	0.8	4
1092	Sexually Transmitted Infections and Sexual Healthcare of Homeless and Street-Involved Youth. , 2020, , 243-270.		1
1093	Geographic and behavioral differences associated with sexually transmitted infection prevalence among Indian men who have sex with men in Chennai and Mumbai. International Journal of STD and AIDS, 2021, 32, 144-151.	0.5	7
1095	British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020. HIV Medicine, 2020, 21, 1-26.	1.0	14
1096	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2020, , 1-22.		0
1097	Real-life occurrence of bacterial sexually transmitted infections among PrEP users: improving the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae with multisite screening. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2021, 63, e76.	0.5	1
1098	HIV Prevention. , 2020, , 85-125.		0
1099	Behavioural Prevention Strategies for STI Control. , 2020, , 49-85.		0
1100	Prevention of HIV Infection. , 2020, , 1-29.		0
1101	Australian interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure prophylaxis (PrEP) access on uptake and service delivery: a qualitative study. Sexual Health, 2020, 17, 485.	0.4	7
1103	The dynamics of a simple, risk-structured HIV model. Mathematical Biosciences and Engineering, 2020, 17, 4184-4209.	1.0	1
1105	Condom use philosophy and behaviors among young men who have sex with men: Variations among HIV pre-exposure prophylaxis users and nonusers. Journal of the American Association of Nurse Practitioners, 2021, 33, 521-528.	0.5	3
1107	Different guidelines for pre-exposure prophylaxis (PrEP) eligibility estimate HIV risk differently: an incidence study in a cohort of HIV-negative men who have sex with men, Portugal, 2014-2018. Eurosurveillance, 2020, 25, .	3.9	3
1108	Using developmental evaluation to implement an oral pre-exposure prophylaxis (PrEP) project in Kenya. Gates Open Research, 0, 4, 158.	2.0	0
1110	HIV-1 prophylactic vaccines: state of the art. Journal of Virus Eradication, 2016, 2, 5-11.	0.3	10

#	ARTICLE	IF	CITATIONS
1111	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-55.	0.3	33
1112	PURLs: On-demand pill protocol protects against HIV. <i>Journal of Family Practice</i> , 2016, 65, 556-8.	0.2	0
1113	InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. <i>Journal of Virus Eradication</i> , 2017, 3, 218-222.	0.3	10
1114	Highlights from the BHIVA Satellite Symposium, IAS Conference, Paris, France, July 2017: 'Tougher times: adapting to increasing demand with declining resources'. <i>Journal of Virus Eradication</i> , 2017, 3, 250-252.	0.3	1
1115	HIV Prevention: Opportunities and Challenges. <i>Topics in Antiviral Medicine</i> , 2017, 24, 123-126.	0.1	7
1116	Maximizing the Benefits of HIV Preexposure Prophylaxis. <i>Topics in Antiviral Medicine</i> , 2018, 25, 138-142.	0.1	22
1117	Sexually Transmitted Infections in the Context of HIV Disease: Clinical Implications. <i>Topics in Antiviral Medicine</i> , 2016, 24, 111-114.	0.1	0
1118	CROI 2016: Hot Spots in HIV Infection and Advances in HIV Prevention. <i>Topics in Antiviral Medicine</i> , 2016, 24, 10-28.	0.1	11
1119	How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. <i>Journal of Virus Eradication</i> , 2018, 4, 215-224.	0.3	34
1120	The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting. <i>Journal of Preventive Medicine and Hygiene</i> , 2020, 61, E451-E463.	0.9	0
1121	Incident Cases of Sexually Transmitted Infections among Users of Pre-Exposure Prophylaxis for HIV Prevention in Honolulu, Hawai'i. <i>Hawai'i Journal of Health & Social Welfare</i> , 2021, 80, 148-154.	0.2	0
1122	Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment. <i>Scientific Reports</i> , 2021, 11, 22252.	1.6	3
1123	Factors that motivate men who have sex with men in Berlin, Germany, to use or consider using HIV pre-exposure prophylaxis—A multi-methods analysis of data from a multicentre survey. <i>PLoS ONE</i> , 2021, 16, e0260168.	1.1	1
1124	High-Fidelity Agent-Based Modeling to Support Prevention Decision-Making: an Open Science Approach. <i>Prevention Science</i> , 2022, 23, 832-843.	1.5	6
1125	HIV Testing and Prevention. , 2022, , 23-43.		0
1126	Sexually Transmitted Infections of the Colon and Rectum. , 2022, , 323-342.		0
1127	Drug and Alcohol Use with Condomless Anal Sex among Men Who Have Sex with Men in Melbourne, Australia: A Retrospective Data Analysis from 2011 to 2017. <i>Archives of Sexual Behavior</i> , 2021, , 1.	1.2	2
1128	HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis. <i>PLoS ONE</i> , 2021, 16, e0259168.	1.1	10

#	ARTICLE	IF	CITATIONS
1129	HIV PrEP access and affordability: a multidisciplinary specialty pharmacy model. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 853-858.	0.7	3
1130	Evaluation of the impact of human immunodeficiency virus pre-exposure prophylaxis on new human immunodeficiency virus diagnoses during the COVID-19 pandemic. <i>International Journal of STD and AIDS</i> , 2022, 33, 99-102.	0.5	2
1131	A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in CÔte d'Ivoire: the ANRS 12381 PRINCESSE project. <i>BMC Public Health</i> , 2021, 21, 2214.	1.2	4
1132	Vital Signs: HIV Infection, Diagnosis, Treatment, and Prevention Among Gay, Bisexual, and Other Men Who Have Sex with Men – United States, 2010–2019. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1669-1675.	9.0	46
1133	Why You Putting This Drug in Your Body to Fight off Something that You Don't Have? Perceptions About PrEP Use Among Black and Latino Men Who Have Sex with Men in the U.S. South. <i>Journal of Homosexuality</i> , 2023, 70, 900-916.	1.3	4
1134	Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. <i>AIDS Patient Care and STDs</i> , 2021, 35, 481-487.	1.1	5
1135	Cost-Effectiveness of Oral Pre-Exposure Prophylaxis and Expanded Antiretroviral Therapy for Preventing HIV Infections in the Presence of Drug Resistance: A Mathematical Modelling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1136	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2021, , 169-190.		0
1137	A Primary Care Intervention to Increase HIV Pre-Exposure Prophylaxis (PrEP) Uptake in Patients with Syphilis. <i>Journal of the International Association of Providers of AIDS Care</i> , 2022, 21, 232595822110733.	0.6	5
1138	Association between the geographic accessibility of PrEP and PrEP use among MSM in nonurban areas. <i>Journal of Rural Health</i> , 2022, , .	1.6	9
1139	Effects Of HIV Oral Pre-Exposure Prophylaxis On Incidence Of STIS Among Female Sex Workers In Selected Drop-In Centers In Nairobi County.. <i>International Journal of Scientific and Research Publications</i> , 2020, 10, 325-333.	0.0	0
1140	Defining the Pre-exposure Prophylaxis Care Continuum Among Recently Incarcerated Men at High Risk for HIV Infection: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2022, 11, e31928.	0.5	3
1141	Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Prescriptions in the United States—A Time-Series Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e1020-e1027.	2.9	28
1142	HIV Pre-Exposure Prophylaxis (PrEP) in a Brazilian Clinical Setting: Adherence, Adverse Events, Sexual Behavior, and Sexually Transmitted Infections. <i>Archives of Sexual Behavior</i> , 2022, 51, 2603-2611.	1.2	3
1143	Abandonment of Human Immunodeficiency Virus Preexposure Prophylaxis Prescriptions at Retail Pharmacies—United States, 2019. <i>Clinical Infectious Diseases</i> , 2022, 75, 512-514.	2.9	6
1144	Past and future of HIV infection. A document based on expert opinion. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 131-156.	0.5	2
1145	The Cost-Effectiveness of HIV/STI Prevention in High-Income Countries with Concentrated Epidemic Settings: A Scoping Review. <i>AIDS and Behavior</i> , 2022, 26, 2279-2298.	1.4	2
1146	Acceptability of HIV pre-exposure prophylaxis in China: A systematic review and meta-analysis. <i>International Journal of STD and AIDS</i> , 2022, 33, 218-231.	0.5	5

#	ARTICLE	IF	CITATIONS
1147	Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab657.	0.4	5
1148	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. <i>Journal of Infectious Diseases</i> , 2022, 226, 510-520.	1.9	13
1149	What makes an optimal delivery for PrEP against HIV: A qualitative study in MSM. <i>International Journal of STD and AIDS</i> , 2022, 33, 322-329.	0.5	4
1150	Gay, bisexual, and other men who have sex with men accessing STI clinics: Optimizing HIV PrEP implementation. <i>PLoS ONE</i> , 2022, 17, e0261705.	1.1	0
1151	Would eligible gay, bisexual and other men who have sex with men use PrEP? Awareness, knowledge, eligibility and intention to use PrEP among EMIS-2017 participants in Spain. <i>Preventive Medicine</i> , 2022, 156, 106962.	1.6	6
1152	AIDS at 40^t&th</th>/sup>&th</th>/sup>: The progress of HIV treatment in Japan. <i>Global Health & Medicine</i> , 2022, 4, 1-8.	0.6	1
1153	Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis. <i>Aids</i> , 2022, 36, 1129-1134.	1.0	18
1154	The Relative Cost-Effectiveness of Long-Acting Injectable Cabotegravir Versus Oral Pre-Exposure Prophylaxis: A Modelled Economic Evaluation and Threshold Analysis in South Africa Based on the HPTN 083 and 084 Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
1155	PrEP Use, Sexual Behaviour, and PrEP Adherence Among Men who have Sex with Men Living in Wales Prior to and During the COVID-19 Pandemic. <i>AIDS and Behavior</i> , 2022, 26, 2746-2757.	1.4	12
1156	UK guideline for the use of HIV postâ€xposure prophylaxisÂ2021. <i>HIV Medicine</i> , 2022, 23, 494-545.	1.0	10
1157	Perceptions and Practicalities Influencing Pre-exposure Prophylaxis Adherence Among Men Who Have Sex with Men in England. <i>AIDS and Behavior</i> , 2022, 26, 2768-2782.	1.4	8
1158	Increased condom use among key populations using oral PrEP in Kenya: results from large scale programmatic surveillance. <i>BMC Public Health</i> , 2022, 22, 304.	1.2	8
1159	Evaluating the cost-effectiveness of a pre-exposure prophylaxis program for HIV prevention for men who have sex with men in Japan. <i>Scientific Reports</i> , 2022, 12, 3088.	1.6	2
1160	Relationships among Substance Use, Sociodemographics, Pre-Exposure Prophylaxis (PrEP) Awareness and Related Attitudes among Young Adult Men Who Have Sex with Men. <i>Substance Use and Misuse</i> , 2022, 57, 786-798.	0.7	5
1161	Adherence, Sexual Behavior and Sexually Transmitted Infections in a New Zealand Prospective PrEP Cohort: 12 Months Follow-up and Ethnic Disparities. <i>AIDS and Behavior</i> , 2022, 26, 2723-2737.	1.4	4
1162	Understanding Influences on Intention to Use Pre-exposure Prophylaxis (PrEP) Among African American Young Adults. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 899-910.	1.8	4
1163	Pre-exposure prophylaxis as prevention strategy in the HIV transmission: characterization of the user. <i>Revista PrevenÃ§Ã£o De InfecÃ§Ã£o E SaÃºde</i> , 0, 8, .	0.0	1
1164	High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 291-299.	0.9	3

#	ARTICLE	IF	CITATIONS
1165	Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta-analysis of global data. <i>Journal of the International AIDS Society</i> , 2022, 25, e25883.	1.2	39
1166	A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 762-766.	0.8	8
1167	Sexually transmitted infections incidence in young Thai men who have sex with men and transgender women using HIV pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2022, , 095646242110567.	0.5	0
1168	Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis. <i>Wellcome Open Research</i> , 0, 7, 108.	0.9	0
1169	Sexually transmitted infections among participants in an HIV PrEP adherence trial. <i>International Journal of STD and AIDS</i> , 2022, 33, 397-403.	0.5	2
1171	A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France. <i>Journal of Virus Eradication</i> , 2022, 8, 100065.	0.3	3
1172	Transmission Clusters, Predominantly Associated With Men Who Have Sex With Men, Play a Main Role in the Propagation of HIV-1 in Northern Spain (2013-2018). <i>Frontiers in Microbiology</i> , 2022, 13, 782609.	1.5	5
1173	Isisekelo Sempilo study protocol for the effectiveness of HIV prevention embedded in sexual health with or without peer navigator support (Thetha Nami) to reduce prevalence of transmissible HIV amongst adolescents and young adults in rural KwaZulu-Natal: a 2x2 factorial randomised controlled trial. <i>BMC Public Health</i> , 2022, 22, 454.	1.2	2
1174	HIV, STI and renal function testing frequency and STI history among current users of self-funded HIV pre-exposure prophylaxis, a cross-sectional study, Germany, 2018 and 2019. <i>Eurosurveillance</i> , 2022, 27, .	3.9	3
1175	HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019. <i>Eurosurveillance</i> , 2022, 27, .	3.9	11
1176	Longitudinal Changes in, and Factors Associated with, the Frequency of Condomless Sex Among People in Care for HIV Infection, HIV Outpatient Study USA, 2007-2019. <i>AIDS and Behavior</i> , 2022, 26, 3199-3209.	1.4	2
1177	Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. <i>Lancet HIV</i> , 2022, 9, e242-e253.	2.1	13
1178	Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. <i>Lancet HIV</i> , 2022, 9, e254-e268.	2.1	66
1179	Attitudes towards, knowledge about, and confidence to prescribe antiretroviral pre-exposure prophylaxis among healthcare providers in Thailand. <i>Medicine (United States)</i> , 2021, 100, e28120.	0.4	8
1180	Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes. <i>Aids</i> , 2022, 36, 561-566.	1.0	11
1182	Oral conditions and salivary analysis in HIV-uninfected subjects using preexposure prophylaxis. <i>Medicina Oral, Patologia Oral Y Cirugía Bucal</i> , 2020, , 0-0.	0.7	2
1183	“We go where we know”: Reflections from Mobilizing for PrEP and Sexual Health (MobPrESH) – A peer-led PrEP education programme across England, for and by women and non-binary people. <i>Women's Health</i> , 2022, 18, 174550572210917.	0.7	5
1184	Interest In and Uptake of HIV Pre-Exposure Prophylaxis (PrEP): A Cross-Sectional Study of High-Risk Patients in Western Canada. <i>Cureus</i> , 2022, , .	0.2	1

#	ARTICLE	IF	CITATIONS
1185	Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project. <i>Global Health, Science and Practice</i> , 2022, 10, .	0.6	0
1186	Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium. <i>AIDS Patient Care and STDs</i> , 2022, 36, 159-167.	1.1	4
1187	Interventions to Increase HIV Testing Uptake in Global Settings. <i>Current HIV/AIDS Reports</i> , 2022, 19, 184-193.	1.1	3
1188	Experiences of men who have sex with men when initiating, implementing and persisting with HIV pre-exposure prophylaxis. <i>Health Expectations</i> , 2022, 25, 1332-1341.	1.1	5
1189	PrEP uptake and delivery setting preferences among clients visiting six healthcare facilities in Eswatini. <i>AIDS and Behavior</i> , 2022, 26, 3345-3355.	1.4	2
1190	Not PrEPared to wait any longer: advocating for the use of PrEP in a HIV prevention strategy. <i>Journal of Global Health Reports</i> , 0, , .	1.0	0
1206	Utilisation of pre-exposure prophylaxis (PrEP) for HIV prevention in the Australian general practice setting: a longitudinal observational study. <i>Sexual Health</i> , 2022, , .	0.4	2
1207	Improving access to pre-exposure prophylaxis for adolescent girls and young women: recommendations from healthcare providers in eastern Zimbabwe. <i>BMC Infectious Diseases</i> , 2022, 22, 399.	1.3	12
1210	A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2022, 10, e25561.	1.8	9
1211	Providing HIV preexposure prophylaxis. <i>Canadian Family Physician</i> , 2022, 68, 197-201.	0.1	0
1213	The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	4
1215	HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review. <i>Frontiers in Medicine</i> , 2022, 9, 881547.	1.2	7
1216	Closing Sexual Health Service Gaps With a New Service Model in Germany: Performance of an on-Site Integrated, Cross-Sectoral, Low Threshold Sexually Transmitted Infections/HIV Counseling and Treatment Service. <i>Frontiers in Public Health</i> , 2022, 10, 793609.	1.3	1
1217	Effectiveness of three delivery models for promoting access to pre-exposure prophylaxis in HIV-1 serodiscordant couples in Nigeria. <i>PLoS ONE</i> , 2022, 17, e0268011.	1.1	0
1218	Sexually Transmitted Infections Among Men and Transgender Women Using HIV Pre-exposure Prophylaxis in a Large Integrated Health System—A Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 91, 1-8.	0.9	1
1219	Conceptualizing safer sex in a new era: Risk perception and decision-making process among highly sexually active men who have sex with men. <i>PLOS Global Public Health</i> , 2022, 2, e0000159.	0.5	1
1220	Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China: A mathematical modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100462.	1.3	8
1221	It's a win for the clinic, it's a win for the frontline, but, most importantly, it's a win for the client: Task Shifting HIV Prevention Services from Clinicians to Community Health Workers in Ontario, Canada. <i>Sexuality Research and Social Policy</i> , 2023, 20, 780-792.	1.4	3

#	ARTICLE	IF	CITATIONS
1222	HIV Pre-Exposure Prophylaxis: What Do Pediatricians Need to Know?. <i>Pediatric Annals</i> , 2022, 51, e191-e195.	0.3	1
1224	Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. <i>BMJ Open</i> , 2022, 12, e048478.	0.8	44
1225	Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis. <i>Scientific Reports</i> , 2022, 12, 8224.	1.6	5
1227	High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Data™AIDS cohort. <i>PLoS ONE</i> , 2022, 17, e0268670.	1.1	6
1228	Medication Non-adherence and Condomless Anal Intercourse Increased Substantially During the COVID-19 Pandemic Among MSM PrEP Users: A Retrospective Cohort Study in Four Chinese Metropolises. <i>Frontiers in Medicine</i> , 2022, 9, 738541.	1.2	3
1229	Usability and effectiveness of adherence monitoring of a mobile app designed to monitor and improve adherence to event-driven and daily HIV pre-exposure prophylaxis among men who have sex with men in Taiwan. <i>Digital Health</i> , 2022, 8, 205520762211027.	0.9	1
1230	Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study. <i>PLoS ONE</i> , 2022, 17, e0268240.	1.1	7
1231	Pharmacokinetics and Efficacy of Topical Inserts Containing Tenofovir Alafenamide Fumarate and Elvitegravir Administered Rectally in Macaques. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1232	Estimating the Impact of PrEP Regimens Containing Long-Acting Injectable Cabotegravir or Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine Among Men Who Have Sex with Men in the United States: Mathematical Modelling for HPTN 083. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1233	PROJECTED IMPACT OF EXPANDED LONG-ACTING INJECTABLE PREP USE AMONG MEN WHO HAVE SEX WITH MEN ON LOCAL HIV EPIDEMICS. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	2
1234	A Case of a Highly Drug-Resistant HIV Detected after Irregular Use of a Self-Prescribed Antiretroviral Drug. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2022, 96, 96-100.	0.0	0
1235	Assessing the impact of HIV pre-exposure prophylaxis scale-up on gonorrhea incidence among gay and bisexual men in Sydney: a mathematical modelling study. <i>Sexually Transmitted Diseases</i> , 0, Publish Ahead of Print, .	0.8	0
1237	Towards achieving the end of the HIV epidemic: Advances, challenges and scaling-up strategies. <i>Clinical Biochemistry</i> , 2023, 117, 53-59.	0.8	1
1238	PrEP use and unmet PrEP-need among men who have sex with men in London prior to the implementation of a national PrEP programme, a cross-sectional study from June to August 2019. <i>BMC Public Health</i> , 2022, 22, .	1.2	5
1239	Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. <i>Lancet Public Health</i> , The, 2022, 7, e529-e536.	4.7	25
1240	PrEP in the Context of Other HIV Risk Reduction Strategies Among Men Who Have Sex with Men: Results from the Flash! PrEP in Europe Survey. <i>Archives of Sexual Behavior</i> , 0, , .	1.2	1
1241	Non-use of combination HIV prevention tools and its determinants among men who have sex with men living in France. <i>Infectious Diseases Now</i> , 2022, 52, 341-348.	0.7	2
1242	Using the <sc>COM&E</sc> model to characterize the barriers and facilitators of pre&Eexposure prophylaxis (PrEP) uptake in men who have sex with men. <i>British Journal of Health Psychology</i> , 2022, 27, 1330-1353.	1.9	4

#	ARTICLE	IF	CITATIONS
1243	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). <i>AIDS and Behavior</i> , 0, , .	1.4	1
1244	The perspectives of street-involved youth who use drugs regarding the acceptability and feasibility of HIV pre-exposure prophylaxis: a qualitative study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 0, , 1-8.	0.6	0
1245	Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life—Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain. <i>AIDS and Behavior</i> , 2022, 26, 4055-4062.	1.4	6
1246	Prevention and Initial Management of HIV Infection. <i>Annals of Internal Medicine</i> , 2022, 175, ITC81-ITC96.	2.0	4
1247	Feasibility and Acceptability of HIV Self-Test Kit Distribution Through PrEP Clients' Social and Sexual Networks to Increase HIV Testing and PrEP Information. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S105-S113.	0.9	7
1249	“œ If it weren’t for my traditional healer, I would be dead” Engaging traditional healers to support people living with HIV in rural Mozambique. <i>PLoS ONE</i> , 2022, 17, e0270565.	1.1	2
1250	The predictive value of macaque models of preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 179-185.	1.5	4
1251	How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 213-221.	1.5	8
1252	Predictors of mHealth use in promoting adherence to pre-exposure prophylaxis among female sex workers: an evaluation of the Jichunge intervention in Dar es Salaam, Tanzania. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	4
1253	Uptake and Acceptability of MyChoices: Results of a Pilot RCT of a Mobile App Designed to Increase HIV Testing and PrEP Uptake Among Young American MSM. <i>AIDS and Behavior</i> , 0, , .	1.4	2
1254	Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial. <i>AIDS and Behavior</i> , 2022, 26, 3950-3962.	1.4	7
1255	Exploring the Role of Provider—Patient Communication in Women’s Sexual Health and Pre-Exposure Prophylaxis Care in the Primary Care Settings in New York State of the United States. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8084.	1.2	0
1256	PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	29
1257	A novel “HIV salience and Perception” scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda. <i>AIDS and Behavior</i> , 2023, 27, 279-289.	1.4	1
1258	Pharmacists and the Next Generation of HIV Pre-Exposure Prophylaxis. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, , .	0.7	2
1259	County-Level Spatiotemporal Patterns of New HIV Diagnoses and Pre-exposure Prophylaxis (PrEP) Use in Mississippi, 2014—2018: A Bayesian Analysis of Publicly Accessible Censored Data. <i>Annals of the American Association of Geographers</i> , 2023, 113, 129-148.	1.5	2
1260	PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, , .	0.2	1
1261	Assessing the Impact of a PrEP Aware Week Campaign on PrEP Prescription Fills in NYS. <i>Journal of Public Health Management and Practice</i> , 2022, 28, 463-468.	0.7	4

#	ARTICLE	IF	CITATIONS
1262	HIV Transmission Prevention. , 2021, , 30-50.		0
1263	Sexual Mixing by HIV Status and Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men: Addressing Information Bias. <i>Epidemiology</i> , 2022, 33, 808-816.	1.2	0
1264	Determinants of PrEP Uptake, Intention and Awareness in the Netherlands: A Socio-Spatial Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8829.	1.2	7
1265	Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1898-1905.	0.5	7
1266	A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	1
1267	Deep learning for topical trend discovery in online discourse about Pre-Exposure Prophylaxis (PrEP). <i>AIDS and Behavior</i> , 0, , .	1.4	3
1268	Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men. <i>AIDS and Behavior</i> , 2023, 27, 719-732.	1.4	6
1269	Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis. <i>Wellcome Open Research</i> , 0, 7, 108.	0.9	0
1270	Risk Factors Associated with Loss to Follow-up Among Transgender Women Receiving HIV Pre-exposure Prophylaxis in Chiang Mai province, Thailand. <i>AIDS and Behavior</i> , 2023, 27, 473-483.	1.4	3
1271	How gender norms and "good girl" notions prevent adolescent girls and young women from engaging with PrEP: qualitative insights from Zimbabwe. <i>BMC Women's Health</i> , 2022, 22, .	0.8	9
1272	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1273	Patient and Physician Preferences Regarding Long-Acting Pre-Exposure Prophylaxis and Antiretroviral Therapy: A Mixed-Methods Study in Southern California, USA. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 856-862.	0.5	2
1274	Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. <i>Journal of Infection and Public Health</i> , 2022, 15, 955-960.	1.9	1
1275	A Qualitative Exploration of Various Stigmas Impacting HIV Pre-Exposure Prophylaxis (PrEP) Uptake Among African American Young Adults. <i>Family and Community Health</i> , 2022, 45, 218-227.	0.5	4
1276	Roll-out of HIV pre-exposure prophylaxis use in France: A nationwide observational study from 2016 to 2021. <i>Lancet Regional Health - Europe</i> , The, 2022, 22, 100486.	3.0	8
1277	Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 24-28.	0.4	5
1278	The effect of PrEP uptake and adherence on the spread of HIV in the presence of casual and long-term partnerships. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 11903-11934.	1.0	0
1279	Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-14.	0.7	0

#	ARTICLE	IF	CITATIONS
1280	A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis. PLoS ONE, 2022, 17, e0272958.	1.1	1
1281	Sources of Information about Pre-Exposure Prophylaxis (PrEP) and Associations with PrEP Stigma, Intentions, Provider Discussions, and Use in the United States. Journal of Sex Research, 2023, 60, 728-740.	1.6	0
1282	Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV. Frontiers in Genetics, 0, 13, .	1.1	2
1284	Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection, 2023, 51, 665-678.	2.3	6
1285	Pre-exposure prophylaxis for HIV: effective and underused. Cmaj, 2022, 194, E1164-E1170.	0.9	0
1287	Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. Clinical Trials, 0, , 174077452211183.	0.7	0
1288	Co-creation using crowdsourcing to promote PrEP adherence in China: study protocol for a stepped-wedge randomized controlled trial. BMC Public Health, 2022, 22, .	1.2	8
1289	Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men. Sexually Transmitted Infections, 0, , sextrans-2022-055499.	0.8	1
1290	Knowledge of viral load, PrEP, and HIV-related sexual risk among men who have sex with men in the Waterloo region. Canadian Journal of Human Sexuality, 0, , .	0.6	0
1291	Perceived influence of alcohol consumption, substance use, and mental health on PrEP adherence and condom use among PrEP-prescribed gay, bisexual, and other men-who-have-sex-with-men: a qualitative investigation. BMC Public Health, 2022, 22, .	1.2	1
1292	The Use of HIV Pre- and Postexposure Prophylaxis Among a Web-Based Sample of HIV-Negative and Unknown Status Cisgender and Transgender Sexual Minority Men: Cross-sectional Study. JMIR Public Health and Surveillance, 2022, 8, e31237.	1.2	4
1293	Integrating enhanced HIV pre-exposure prophylaxis into a sexually transmitted infection clinic in Lilongwe (ePrEP STI): A prospective cohort study (Preprint). JMIR Research Protocols, 0, , .	0.5	0
1294	A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP. International Journal of STD and AIDS, 2022, 33, 1183-1192.	0.5	2
1296	Examining provincial PrEP coverage and characterizing PrEP awareness and use among gay, bisexual and other men who have sex with men in Vancouver, Toronto and Montreal, 2017â€“2020. Journal of the International AIDS Society, 2022, 25, .	1.2	6
1297	Out-of-pocket Expenses and Time Spent on Clinic Visits Among HIV Pre-exposure Prophylaxis Users and Other Clinic Attendees in Eswatini. AIDS and Behavior, 0, , .	1.4	4
1298	â€œIt will not be easy to acceptâ€ Parents conflicting attitudes towards pre-exposure prophylaxis for HIV prevention amongst adolescent girls and young women. Research in Social and Administrative Pharmacy, 2023, 19, 266-271.	1.5	1
1299	Retrospective audit of a convenience cohort of individuals on HIV pre-exposure prophylaxis in Alberta, Canada. Jammi, 0, , .	0.3	0
1300	Between- and Within-Individual Sociodemographic and Psychological Determinants of PrEP Adherence Among Men Who have Sex with Men Prescribed a Daily PrEP Regimen in Wales. AIDS and Behavior, 0, , .	1.4	1

#	ARTICLE	IF	CITATIONS
1301	The epidemiological impact and cost-effectiveness of key population-led PrEP delivery to prevent HIV among men who have sex with men in Thailand: A modelling study. , 2022, 7, 100097.		0
1302	Same-Sex Marriage Laws, Provider-Patient Communication, and PrEP Awareness and Use Among Gay, Bisexual, and Other Men Who have Sex with Men in the United States. AIDS and Behavior, 2023, 27, 1897-1905.	1.4	2
1303	The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. Dialogues in Clinical Neuroscience, 2022, 24, 10-69.	1.8	16
1304	Understanding Oral Prep Interest Among South African Adolescents: The Role of Perceived Parental Support and PrEP Stigma. AIDS and Behavior, 2023, 27, 1906-1913.	1.4	2
1305	Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers. BMC Women's Health, 2022, 22, .	0.8	12
1307	Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques. EBioMedicine, 2022, 86, 104338.	2.7	5
1308	An overview of programmatic indicators to monitor the roll-out of HIV preexposure prophylaxis. Aids, 2023, 37, 1-17.	1.0	1
1310	Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research. Current Opinion in HIV and AIDS, 2023, 18, 1-11.	1.5	3
1311	The relationship between HIV pre-exposure prophylaxis, sexually transmitted infections, and antimicrobial resistance: a qualitative interview study of men who have sex with men. BMC Public Health, 2022, 22, .	1.2	2
1312	Interventions to increase the uptake and continuation of pre-exposure prophylaxis (PrEP) by adolescent girls and young women at high risk of HIV in low-income and middle-income countries: a scoping review. BMJ Global Health, 2022, 7, e009474.	2.0	5
1313	Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?. HIV Medicine, 2023, 24, 653-663.	1.0	5
1314	Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trial. Lancet HIV, 2022, 9, e838-e847.	2.1	15
1315	Pre-exposure prophylaxis in France: How many MSM are eligible and how much will it cost?. PLoS ONE, 2022, 17, e0278016.	1.1	0
1316	PrEP stigma among current and non-current PrEP users in Thailand: A comparison between hospital and key population-led health service settings. Frontiers in Public Health, 0, 10, .	1.3	3
1317	Spotlight on Research. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2022, 14, 524-524.	0.0	0
1318	Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention. Frontiers in Immunology, 0, 13, .	2.2	4
1319	The role of machine learning in HIV risk prediction. Frontiers in Reproductive Health, 0, 4, .	0.6	2
1320	Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years' Experience. Infectious Diseases and Therapy, 2023, 12, 425-442.	1.8	2

#	ARTICLE	IF	CITATIONS
1321	Knowledge of viral load, PrEP, and HIV-related sexual risk among men who have sex with men in the Waterloo region. <i>Canadian Journal of Human Sexuality</i> , 2022, 31, 397-408.	0.6	0
1322	Self-start HIV postexposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy. <i>Sexually Transmitted Infections</i> , 2023, 99, 367-372.	0.8	2
1323	Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using <sc>HIV</sc> Recent Infection Assays: A Consensus Statement from the Forum <sc>HIV</sc> Prevention Trial Design Project. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 29-40.	2.3	4
1324	Prevalence of renal and bone risk factors among individuals prescribed oral pre-exposure prophylaxis for HIV. <i>IJID Regions</i> , 2023, 6, 68-75.	0.5	1
1325	Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100416.	1.5	2
1326	Psychometric Properties of an Adapted Stigma Scale and Experiences of Stigma Associated with HIV Pre-exposure Prophylaxis Use Among Men Who have Sex with Men: A Mixed Methods Study. <i>AIDS and Behavior</i> , 2023, 27, 2397-2410.	1.4	1
1327	Intervention treatment distributions that depend on the observed treatment process and model double robustness in causal survival analysis. <i>Statistical Methods in Medical Research</i> , 2023, 32, 509-523.	0.7	1
1328	PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future. <i>Vaccines</i> , 2023, 11, 122.	2.1	3
1329	HIV Pre-exposure Prophylaxis Persistence and Adherence Among Men Who Have Sex With Men in Four US Cities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 34-41.	0.9	4
1330	Prophylaxie prÃ©exposition au VIH : efficace et sous-utilisÃ©e. <i>Cmaj</i> , 2022, 194, E1544-E1550.	0.9	0
1332	Economic Burden of HIV in a Commercially Insured Population in the United States. <i>Journal of Health Economics and Outcomes Research</i> , 0, , 10-19.	0.6	0
1334	Economic Burden of HIV in a Commercially Insured Population in the United States. <i>Journal of Health Economics and Outcomes Research</i> , 2023, 10, .	0.6	0
1335	HIV pre-exposure prophylaxis (PrEP) knowledge among general practitioners in 2020: A French survey. <i>Infectious Diseases Now</i> , 2023, 53, 104649.	0.7	1
1336	Uptake, Adherence and Retention of Daily Oral Pre-Exposure Prophylaxis among Female Sex Workers in the Greater Gaborone City, Botswana. <i>International STD Research & Reviews</i> , 0, , 12-24.	0.2	0
1338	MSM with HIV: Improving prevalence and risk estimates by a Bayesian small area estimation modelling approach for public health service areas in the Netherlands. <i>Spatial and Spatio-temporal Epidemiology</i> , 2023, 45, 100577.	0.9	4
1339	Health Literacy as a Mediator of the Relationship Between Socioeconomic Position and Pre-Exposure Prophylaxis Uptake Among Men Who Have Sex with Men Living in France. <i>Health Literacy Research and Practice</i> , 2023, 7, .	0.5	1
1340	Perception of <sc>PrEP</sc>-related stigma in <sc>PrEP</sc> users: Results from the <sc>ANRSâ€PREVENIR</sc> cohort. <i>HIV Medicine</i> , 2023, 24, 938-945.	1.0	1
1341	Prospective Single-Center Cohort Study on HIV Pre-exposure Prophylaxis Reveals Transient but Relevant Elevations in Transaminase Levels in Some Participants Albeit Otherwise High Tolerability. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, e1-e3.	0.9	0

#	ARTICLE	IF	CITATIONS
1342	Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study. <i>Chinese Medical Journal</i> , 2022, 135, 2730-2737.	0.9	1
1343	High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. <i>Journal of Community Health</i> , 2023, 48, 513-521.	1.9	4
1345	Utility of a machine-guided tool for assessing risk behaviour associated with contracting HIV in three sites in South Africa. <i>Informatics in Medicine Unlocked</i> , 2023, 37, 101192.	1.9	1
1346	HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England. <i>Journal of Infection</i> , 2023, 86, 245-247.	1.7	2
1347	Multi-dimensional mismatch and barriers for promoting PrEP among men who have sex with men in China: a cross sectional survey from the Demand-side. <i>AIDS Research and Therapy</i> , 2023, 20, .	0.7	1
1348	Predicting and influencing PrEP use: the role of motivational and attitudinal factors. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 1354-1364.	0.6	0
1349	Barriers to uptake of PrEP across the continuum among transgender women: A global scoping review. <i>International Journal of STD and AIDS</i> , 2023, 34, 299-314.	0.5	6
1350	Roll-out and effectiveness of HIV pre-exposure prophylaxis in France: An overview. <i>Therapie</i> , 2023, , .	0.6	0
1351	Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study. <i>PLoS ONE</i> , 2023, 18, e0280339.	1.1	0
1352	World AIDS day. <i>International Paramedic Practice</i> , 2023, 13, 1-1.	0.1	0
1354	Examining Associations Between Resilience and PrEP Use Among HIV-negative GBM in Toronto, Montreal and Vancouver. <i>AIDS and Behavior</i> , 2023, 27, 3109-3121.	1.4	2
1355	Community pharmacists's acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV). <i>Canadian Pharmacists Journal</i> , 2023, 156, 137-149.	0.4	3
1356	Post-exposure and pre-exposure prophylaxis as HIV preventive measures. <i>Zdravstvena Zastita</i> , 2022, 51, 32-45.	0.0	0
1357	Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya. <i>Journal of the International AIDS Society</i> , 2023, 26, .	1.2	2
1358	Pandemic HIV and its legacy for medicine and global health. <i>Clinical Medicine</i> , 2023, 23, 106-114.	0.8	2
1359	Process description of developing HIV prevention monitoring indicators for a province-wide pre-exposure prophylaxis (PrEP) program in British Columbia, Canada. <i>PLoS ONE</i> , 2023, 18, e0283025.	1.1	0
1360	Would men who have sex with men support less frequent screening for asymptomatic chlamydia and gonorrhoea to improve antibiotic stewardship? A qualitative study. <i>Sexual Health</i> , 2023, 20, 148-157.	0.4	4
1361	Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysis via CiteSpace. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0

#	ARTICLE	IF	CITATIONS
1362	Exploring the causes of preexposure prophylaxis of HIV failure—future developments for overcoming the same—a mini review. <i>Journal of Human Virology & Retrovirology</i> , 2019, 7, 1-5.	0.1	1
1363	Perspectives of Young Men Who Have Sex with Men on PrEP Adherence and Peer Navigation: A Qualitative Study. <i>Archives of Sexual Behavior</i> , 2023, 52, 2037-2049.	1.2	3
1364	Comparison of the effectiveness of different HIV-1 prevention methods, and their mechanisms.. , 0, 36, 675-681.		0
1365	HIV pre-exposure prophylaxis: It is time to consider harm reduction care for adolescents in Canada. <i>Paediatrics and Child Health</i> , 0, , .	0.3	0
1366	Increasing Participation in a TelePrEP Program for Sexual and Gender Minority Adolescents and Young Adults in Louisiana: Protocol for an SMS Text Messaging—Based Chatbot. <i>JMIR Research Protocols</i> , 0, 12, e42983.	0.5	5
1367	Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. <i>Hepatology</i> , 2023, 77, 2084-2092.	3.6	8
1368	Interdisciplinarity in HIV prevention research: the experience of the PrEP1519 study protocol among adolescent MSM and TGW in Brazil. <i>Cadernos De Saude Publica</i> , 2023, 39, .	0.4	15
1369	Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17—24years old. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
1370	Prediction of Sex and the Potential Use of On-Demand PrEP Among Young Men Who Have Sex With Men in the U.S.. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, Publish Ahead of Print, .	0.9	0
1371	Electronic health records to capture primary outcome measures: two case studies in HIV prevention research. <i>Trials</i> , 2023, 24, .	0.7	0
1372	HIV Pre-Exposure Prophylaxis Use on a Global Scale Among Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. <i>AIDS Patient Care and STDs</i> , 2023, 37, 159-191.	1.1	1
1373	Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa. <i>Clinical Infectious Diseases</i> , 2023, 77, 606-614.	2.9	6
1374	More than prevention: early adoption of HIV pre-exposure prophylaxis (PrEP) by gay and bisexual men in New Zealand. <i>Culture, Health and Sexuality</i> , 2024, 26, 222-235.	1.0	0
1375	Causal Effects of Stochastic PrEP Interventions on HIV Incidence Among Men Who Have Sex With Men. <i>American Journal of Epidemiology</i> , 2024, 193, 6-16.	1.6	0
1376	Insights into barriers and facilitators in PrEP uptake and use among migrant men and transwomen who have sex with men in Belgium. <i>BMC Public Health</i> , 2023, 23, .	1.2	3
1377	Geosexual Archetype, Preventive Behaviours, and Sexually Transmitted Infections among High Risk Men who Have Sex with Men. <i>Sexually Transmitted Diseases</i> , 0, Publish Ahead of Print, .	0.8	0
1378	Barriers and facilitators to <sc>HIV Pre—Exposure</sc> Prophylaxis (<sc>PrEP</sc>) in Specialist Sexual Health Services in the United Kingdom: A systematic review using the <sc>PrEP</sc> Care Continuum. <i>HIV Medicine</i> , 2023, 24, 893-913.	1.0	7
1379	Exploring Current Practice, Knowledge, and Challenges of Sexually Transmitted Infection/HIV Management and Pre-Exposure Prophylaxis Among Japanese Health Care Professionals: A Cross-Sectional Web Survey. <i>AIDS Patient Care and STDs</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1408	HIV/AIDS Prevention. , 2024, , 139-151.		0